
==== Front
Mol Cancer
Mol Cancer
Molecular Cancer
1476-4598
BioMed Central London

2104
10.1186/s12943-024-02104-w
Review
Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes
Sun Yikan 1234
Yinwang Eloy 1234
Wang Shengdong 1234
Wang Zenan 1234
Wang Fangqian 1234
Xue Yucheng 1234
Zhang Wenkan 1234
Zhao Shenzhi 1234
Mou Haochen 1234
Chen Shixin 1234
Jin Lingxiao 1234
Li Binghao libinghao@zju.edu.cn

1234
Ye Zhaoming yezhaoming@zju.edu.cn

1234
1 https://ror.org/059cjpv64 grid.412465.0 Department of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang China
2 https://ror.org/00a2xv884 grid.13402.34 0000 0004 1759 700X Orthopedics Research Institute of Zhejiang University, Hangzhou, Zhejiang China
3 grid.412465.0 Key Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, Zhejiang China
4 https://ror.org/059cjpv64 grid.412465.0 Department of Orthopedics, Musculoskeletal Tumor Center, The Second Affiliated Hospital of Zhejiang, University School of Medicine, Hangzhou, 310009 China
9 9 2024
9 9 2024
2024
23 19323 5 2024
30 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
CD8+ T cells are the workhorses executing adaptive anti-tumour response, and targets of various cancer immunotherapies. Latest advances have unearthed the sheer heterogeneity of CD8+ tumour infiltrating lymphocytes, and made it increasingly clear that the bulk of the endogenous and therapeutically induced tumour-suppressive momentum hinges on a particular selection of CD8+ T cells with advantageous attributes, namely the memory and stem-like exhausted subsets. A scrutiny of the contemporary perception of CD8+ T cells in cancer and the subgroups of interest along with the factors arbitrating their infiltration contextures, presented herein, may serve as the groundwork for future endeavours to probe further into the regulatory networks underlying their differentiation and migration, and optimise T cell-based immunotherapies accordingly.

Keywords

CD8+ T cells
Tumour-infiltrating lymphocytes
T cell nomenclature
T cell exclusion
Caner immunotypes
Cancer immunotherapy.
National Natural Science Foundation of China82273178 82273178 82273178 82273178 82273178 82273178 82273178 82273178 82273178 82273178 82273178 82273178 82273178 Zhejiang Province Traditional Chinese Medicine Science and Technology Plan2023ZR108 2023ZR108 2023ZR108 2023ZR108 2023ZR108 2023ZR108 2023ZR108 2023ZR108 2023ZR108 2023ZR108 2023ZR108 2023ZR108 2023ZR108 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Tumour infiltrating lymphocytes (TILs) are the frontliner immune cells that populate the tumour microenvironment (TME), the very interface of cancer-immunity confrontation, in solid tumours. CD8+ T lymphocytes are considered one of if not the most important constituents of TILs with quasi-universal prognostic benefits owing to their capability to unleash direct cytotoxicity upon encounter with tumour cells expressing the cognate antigen [1, 2]. In reality, however, the presence or even abundance of CD8+ TILs per se does not consistently translate into tumour control or regression, favourable survival outcomes, or response to T-cell-based immunotherapy to the same effect size [3], suggesting failure to divulge relevant modifying factors through undifferentiated evaluation of all CD8+ T cells as a congruent whole. Recent advances in high-throughput, high-definition cellular characterisation modalities such as single-cell RNA sequencing (scRNA-seq), T cell receptor sequencing (TCR-seq), and Assay for Transposase Accessible Chromatin with high-throughput sequencing (ATAC-seq) have uncovered an unprecedented level of CD8+ TIL heterogeneity [4], while spatial transcriptomic (ST) technologies have enabled faithful reconstructions of the positional details inevitably lost during the tissue dissociation process required for scRNA-seq, permitting in-depth analysis of the contact-mediated and paracrine actions between cell populations that are intrinsically location-dependent [5]. Accumulating data on the immensely complex multi-omic landscape of CD8+ TILs suggest that only subpopulations with certain functional and differentiation statuses are empowered by the pre-requisite molecular machinery and stand at the immunological vantage points to act as the principal mediators of anti-tumour immunity and response to immunotherapy [6].

The blowout of high-dimensional data has nonetheless stirred up a taxonomical kerfuffle as it inundates the conventional T-cell classification systems. Before advancing the discussion, it is therefore crucial to reiterate the inherent limitations of the current T cell nomenclature and the caveats when making inferences based on it. Any cell clustering or annotation attempts are more or less arbitrary in nature and at risk of misinterpreting or under-representing the true biological significance of cells. Functional overlaps between pre-defined cell populations frequently exist, and misclassification is common. Besides, the transition from one distinguishable cell phenotype to another routinely involves a gradual, uninterrupted spectrum, but overly refined discretisation to meticulously mirror the continuum may produce unjustified sophistication and compromise generalisability, thus calling for an optimal resolution to meaningfully group cells.

A reference cell tree brilliantly named ‘consensus ontology’ has been envisaged, where the collection of all given cells in both physiological and pathological states over the lifespan of an organism can be moulded into a three-dimensional tree-like architecture with lineage, differentiation, and elapsed time being the localising axial parameters, decorated with the key transcriptional programmes, molecular features, signalling pathways, and, where relevant, spatial information of the cells [7]. Such an epochal idea has provided much inspiration for this review, where we aim to present a lineage-orientated, function-centred panorama of the CD8+ TILs based on prevailing immunological knowledge, zoom in on the subpopulations of interest with regard to anti-cancer immunity and therapeutic benefits, and complement the discussion with pivotal cell-extrinsic and spatial determinants of their successful tumour infiltration.

CD8+ T cell evolution in cancer

Early T cell activation

Naïve CD8+ T cells (TN) are the positively and negatively selected, heterodimeric αβTCR-bearing, and lineage-committed single positive (CD4−CD8+) T cells that have not encountered the cognate antigen. Cytometric definition of TN entails exclusive expression of the CD45RA isoform of leukocyte common antigen (CD45RA+CD45RO−) along with auxiliary naïve T cell markers, many of which are homing receptors such as C-C motif chemokine receptor 7 (CCR7) and CD62L (also known as L-selectin) that allows homing to lymphoid organs and tissues via blood circulation and then manoeuvring through the white pulp of the spleen or the T cell zone of lymph nodes to survey antigens. They are the last common precursors that beget all CD8+ T cell subtypes found in the secondary lymphoid organs (SLOs) and tumours [1, 8]. There exist numerous obstacles that act as physiological deterrents to autoimmunity and need to be surmounted before TN can be activated to effectors (TEFF) with the full tumoricidal potential. In nascent tumorigenesis, immunologic ignorance can occur when pathological expression of tumour-associated self-antigens is below threshold, not displaying a recognisable differential pattern, or restricted to the immune-privileged sites; or when transformed cells expressing tumour-specific neoantigens are shielded by surrounding tissues from detection and translocation to tumour-draining lymph nodes (TDLNs) for T cell priming. On the other hand, antigen recognition in the absence of a co-stimulus or signal transduction and augmentation by dedicated antigen-presenting cells (APCs) in an appropriately conditioned inflammatory milieu results in a hyporesponsive ‘anergic’ state of CD8+ T cells with limited proliferative and effector capacities [9]. Meanwhile, over-exposure to self-antigens can induce a ‘tolerised’ state that is deficient in cytotoxicity and prone to apoptosis, a phenomenon known as ‘peripheral deletion’ [10, 11].

In the meantime, the effector-memory equilibrium is known to be under tight regulation of orchestrated, potentially antigen-independent, and frequently counterbalancing determinants in relation to cytokines (e.g., effector-predisposing interleukin-12 [IL-12], and IFN-γ versus memory-favouring IL-7, IL-15, IL-21, and transforming growth factor [TGF]-β), TCR signal strength and antigen affinity, antagonising transcription factor duos (e.g., pro-effector T-bet versus pro-memory Eomesodermin, BLIMP-1 versus BCL-6, ID2 versus ID3, and STAT4 versus STAT3), epigenetic remodelling, and metabolic machineries [12]. Resolution of an acute infection customarily leads to a clear-cut inclination towards memory differentiation, survival and self-renewal under the composite force of the regulatory network [13]. In contrast, with an unremitting threat such as a developing tumour, differing chronology of antigen exposure and stimulation precludes fate unambiguity and accentuates the relevance of the variant, intermediate, and hybrid states of memory, effector, and exhausted CD8+ T cells. An entr’acte from constant antigen stimulation, most commonly in the refuge of TDLNs [14, 15] and the blood circulation, is of utmost importance in initiating the memory-associated programmes while postponing the path to exhaustion, a fate ultimately manifested in most tumour-reactive CD8+ T cells [4, 10, 14, 16–19].

The transmuted memory lane in cancer

Immunological memory denotes the ability to stage a more expeditious and pronounced response upon re-encounter with an earlier insult. Stemness and migrating capacity are the two pillars that uphold the depth (that is, the stretches of the possible effector progenies) and breadth (the tissue versatility and specificity) of the immune protection memory CD8+ T cells (TMEM) are capable of evoking. A substantial proportion of TMEM continually traverse the blood and/or the lymphatics to maximise the antigen screening range. The circulating TMEM were initially divided into central memory cells (TCM) and effector memory cells (TEM) based on expression of CCR7 and CD62L (thus having access to lymphoid tissue), or the lack thereof, respectively [20]. Subsequent investigation has revealed the extraordinary longevity and tremendous developmental and proliferative potentials of TCM [21–25]. Additionally, stem cell memory T cells (TSCM) have been identified as a body of CD45RA+IL-7Rα+ cells sharing overlapping cardinal memory and recirculation features with TCM but are even less differentiated and demonstrate enhanced self-renewal, plasticity, and multipotency [26–30], though Galletti et al. have demonstrated that the apparent gene expression profile differences could very well be accounted for by differential inclusion of PD-1+TIGIT+ progenitors committed to exhausted-like progenies [31]. TEM, in comparison, are characterised by non-lymphoid tissue (NLT) tropism, more immediate effector functions upon restimulation, but less secondary expansion capacity [25].

Although TCM and TSCM are abundant in the peripheral blood of cancer patients [17] and theoretically constitute a systemic reserve of effector CD8+ TILs, such untainted memory phenotypes are difficult to maintain with the systemic perturbations and local TME of tumour-bearing individuals. Tumour-specific bona fide memory cells have been identified in TDLNs [14], but a plethora of single-cell and TCR-profiling studies on melanoma [18], hepatocellular carcinoma [32], colorectal carcinoma [33], and pan-cancer types [4] have unanimously indicated that infiltrating CD8+ T cells that are tumour-reactive almost exclusively reside in an exhausted state of various degrees, and that the heavily expanded, cancer antigen-recognising intra-tumoural TCR clonotypes are rarely detected in the memory compartment of the peripheral circulation [18]. This could suggest inadequate development of a circulating memory repertoire specifically targeting tumours across different cancer types, and even if spawned, these memory cells may be rapidly depleted after mobilisation. Therefore, the precise size of the circulating tumour-reactive memory compartment and magnitude of contribution from these cells to naturally occurring anti-cancer immunity prior to acquiring exhaustion features are to be further assessed in human cancers.

That being said, the superior proliferative potential of TCM and TSCM can be leveraged in various forms of cancer immunotherapies. TSCM can be generated ex vivo from naïve precursors using clinical-grade culture protocols utilising IL7 and IL15 [27], or a combination of IL-7, IL-21 and the WNT agonist TWS119 [34]. Recently, MEK inhibition has also been shown to be capable of inducing TSCM and functionally superior TCM [30]. Compared to chimeric antigen receptor (CAR)-T cell therapy derived from unselected T cells, adoptive transfer of CAR-TSCM and TCM have engendered expanded, persistent, and intensified anti-tumour responses against haematologic malignancy xenografts [34–36] with reduced risk of cytokine release syndrome [35], and, in combination with PD-1 blockade, achieved tumour control in OVCAR-3-inoculated mice [37]. Likewise, engineered expression of IL-7 along with CCL19 on CAR-T cells boosted memory responses to solid tumours and prolonged survival in mice [38].

Tissue-resident memory

The observation of ample long-lived, TEM-like CD8+ T cells in NLT heralded the revelation of tissue-resident memory T cells (TRM) [39], which have been formally recognised with skin [40] and intestinal [41] transplantation in murine models and subsequently found prevalent in SLOs and both barrier and non-barrier tissues in mice and humans [42, 43]. The non-migratory nature of TRM stems from the expression of integrins CD49a and CD103, the latter of which is the integrin subunit αE (ITGAE) that serves as a canonical TRM marker, and CD69, an early activation marker and down-regulator of relocation-promoting sphingosine 1-phosphate receptor-1 (S1PR1), in addition to a concomitant lack of tissue egress mediators [42, 43]. An array of universal (e.g., CXCR6 and VIM) and site-specific (e.g., CCR4, CCR10, and CXCR4 for skin versus CCR9 for small intestine predilection) cell matrix and adhesion molecules also reliably delineate TRM [44, 45]. Additionally, upregulation of transcription factors (TFs) such as BLIMP-1, HOBIT, RUNX3 and NOTCH is pivotal to TRM formation and has further instituted TRM as separate entities to the circulating memory T cells in mouse models [46–48]. Suppression of KLF2 is another TRM hallmark that provides an additional binding force for TRM to the surrounding tissue via resultant down-regulation of S1PR1 [49]. Many of these TRM-enriched TFs, including Runx3, Notch, and Hif1a, are known harbingers of effector T cell functions, which underlie the phenotypic preparedness of TRM in repelling invading pathogens and rejecting transformed cells [47, 48, 50]. However, it remains uncertain the extent to which the core transcriptional signature is shared with human TRM. Notwithstanding the discrepancies in Hobit expression pattern [48], recent studies have corroborated perpetuation of some of these TRM TFs in humans, and identified other ones of interest such as AHR, KLF4, and Hic1 [44, 51, 52].

Mounting evidence has brought TRM to the centre of attention in quelling numerous cancers, particularly those of epithelial origins. It has been recognised that TRM cells are central to immunosurveillance, especially in tissue compartments not readily accessible by circulating memory, as well as curtailment and, in an ideal situation, prompt elimination of transformed cells and subclinical tumours, analogous to their presumed contribution in local containment of latent viruses [53–56]. Park et al. have notably shown in their seminal work that tumour-specific TRM unfailingly prevented melanoma development upon rechallenge independent of circulating memory depletion, and upon TRM knockdown, tumour outgrowth manifested in approximately 20% of mice with occult melanomas [54]. This is echoed by TRM-mediated protection against secondary breast tumour rechallenge in the ipsi- but not contralateral mammary fat pad [55]. TRM can also derive from intratumoural TMEM/TEM [57] and reside in the lymph nodes [58], offering protection against metastases at distant sites. Furthermore, tumour-associated clones of TRM generated post-immune checkpoint blockade (ICB) were able to persist for up to 9 years [59], illustrating the long-lasting protection that TRM confer. The consequent selective pressure from TRM immunosurveillance, however, may paradoxically favour the clonal growth of cancer cells that are adept at immune evasive and suppressive manoeuvres, such as the cases in lung cancers where tumour cells escape TRM hammering by down-regulation of MHC-I molecules [60] and engaging epithelial-to-mesenchymal transition [61], which epitomises the phenomenon of immunoediting that signifies the complex dynamic of the cancer-immunity equilibrium [62].

In established solid tumours of many types, enrichment of TRM transcriptomic signatures in tumours is also found invariably correlated with more intense anti-tumour activity with respect to cytolytic molecule expression and pro-inflammatory cytokine release, and better prognoses, irrespective of the overall amount of CD8+ T cell infiltrates [59, 63–71]. As known expressors of immune checkpoint molecules [63, 66, 71, 72], infiltrating TRM represent one of the prime salvageable targets of ICB therapy [55, 67, 71, 73, 74], where reinvigoration and expansion of TRM have been consistently observed following ICB, and pre-treatment TRM signature prognosticated response to ICB-based regimens [71, 73]. However, accurate measurement of the anti-tumour momentum and therapeutic efficacy attributable to conventional TRM and their progenies is challenging due to the entangled CD8+ T cell fates within the TME, as TILs with TRM-like phenotypes could very well develop from activated T cells of distinct lineages secondarily acquiring TRM features [55, 70, 75, 76]. Gavil et al. have demonstrated that, in the context of a tumour, the common TRM markers (CD69 and CD103) failed to reflect tumour residence, nor did CD62L exclude the same [75]. Instead, chronic antigen stimulation endowed incoming tumour-specific CD8+ T cells with a distinct resident programme that matured in concert with exhaustion [75]. TME factors such as TGF-β, which is known to induce CD103 [52, 61, 68, 77], could also be contributing. Furthermore, recently conducted in-depth TIL characterisation studies have resolved TRM subpopulations of extended significance. In tumours and vitiligo-affected skins of metastatic melanoma patients who responded well to immunotherapy, subcluster of TRM distinguished by abundant expression of certain pro-inflammatory cytokines and chemokines predicted better patient overall survival among other clinical variables, whereas the TRM cluster defined by TCR signalling transcripts did not [59]. In ovarian cancers, a group of progenitor TRM descended from a recently activated CD103−CD69+ re-circulating population was pinpointed as the reservoir of tumour-reactive effectors and associated with improved outcomes [70]. Therefore, additional investigations are warranted for more rigorous ways to distinguish bona fide TRM from TRM-like cells in the TME and resolve the subsets with the most tumoricidal capacity and the manipulable therapy targets.

The transcriptomic and epigenetic stigmata of exhaustion

Exhaustion entails the compromise in anti-tumour immunity due to prolonged stimulation of immune cells, which ubiquitously occurs in tumour-reactive CD8+ TILs and leads to dwindling overall magnitude of T cell anti-tumour response in the long term [78]. TCR activation is naturally an antecedent to and propagator of T cell exhaustion. Low-affinity interactions usually lead to functional inertness or failure to instigate a self-sustaining tumour-reactive T cell population [79], whereas exceedingly strong TCR signals may predispose tumour-reactive CD8+ T cells to accelerated exhaustion [80–82]. A minimum length of time is also required for initiation towards exhaustion differentiation [15, 83, 84], as evidenced by conserved lineage flexibility of virus-specific CD8+ T cells when removed from chronic infection in the first weeks [85], and yet the time point at which CD8+ T cells commit to the exhaustion fate in cancer remains a subject of active investigation. Recently, an interrogation of chromatin accessibility and transcriptomic alterations of early activated CD8+ T cells in tumour-bearing mice has revealed that acquisition of exhaustion hallmarks commenced as early as within 6 h of tumour antigen exposure, well in advance of the previously thought timeframe of days to short weeks [86]. Also, elements of exhaustion (loss of effector function, upregulation of immune checkpoint molecules, and contracted proliferative capacity) are regulated independently and ripen asynchronously [86–88], where, for instance, IFN-γ and TNF loss preceded that of proliferative capacity by a large margin [86]. These findings suggest that extrapolation of CD8+ T cell exhaustion state from isolated parameters is an error-prone and misleading practice, and instead an all-inclusive, weighted scoring fabric may be necessitated.

Liberal usage of the term ‘exhaustion’ frequently constitutes a misnomer in that cells commonly designated as exhausted CD8+ T cells (TEX) encompass a wide spectrum that spans across near-complete preservation of function to absolute indolence [4, 89], and that the degree of reprogrammability by ICB is not indicated by the somewhat deceptive terminology [90]. Despite these variations, once lineage committed, all TEX are, without exception, constrained by the transcriptional rewiring and epigenetic scarring that persisted in progenies and precluded complete reversal to the pristine naïve or memory-level of functional reserve even after antigen withdrawal [31, 91, 92]. TCR signalling-mediated upregulation of nuclear factor of activated T-cells (NFAT) family of TFs lays the foundation for the extensive and incompletely understood regulatory network of interdependent TFs that perpetuate the exhaustion programme [84]. NFAT holds critical roles in both T cell activation/effector function and tolerance/exhaustion, the former of which typically requires partnering of NFAT with AP-1 proteins [93]. With relative scarcity of AP-1 secondary to, for instance, insufficient MAPK signalling from inadequate co-stimulation, uncomplexed NFAT is diverted to monomeric binding motifs unaccompanied by an adjacent AP-1 site, inducing transcription of exhaustion-related genes encoding inhibitory molecules (e.g., Pdcd1 [encoding PD-1], Lag3, Havcr2 [TIM3], Tigit, Ctla4) and repressive TFs (e.g., Tox, Egr1, Egr2, and Nr4a) [86–88, 93–97]. In conformation with the dynamics of the down-stream transcripts, NFAT motifs are enriched in the differentially accessible chromatin regions of TEX [84, 86, 97], and the predicted NFAT binding sites in the exhaustion-related genes also increased in accessibility [87, 88]. The partner-dependent functional bivalency of NFAT provides an opening for manipulating the exhaustion-versus-effector differentiation, where overexpressing c-Jun, a canonical AP-1 factor, granted the CAR T cells exhaustion resistance [98]. Akin to NFAT, BATF has bipartite roles after TCR signalling induction, and overexpressing BATF promoted BATF-IRF4 cooperation, thereby skewing CAR TILs towards an effector phenotype [99].

Among other NFAT-induced TFs, TOX has gained recognition in recent years as an essential potentiator of exhaustion [87, 92, 100–102], without which differentiation into TEX is averted altogether [100, 103]. Although acute infections saw temporary presence of TOX at low levels, sustained high-intensity TOX expression in chronic infections and tumours upregulates inhibitory receptors, further modulates the TF network, and eventually engraves modification of the corresponding exhaustion-specific chromatin landscape in an NFAT-independent, self-propagating manner [84, 87, 100], thereby inflicting the indelible epigenetic scars on TEX that forbid them from full recovery of memory/effector functions after antigen withdrawal [92] or ICB rescue [104]. With that said, TOX-knockout tumour-specific T cells failed to persevere in tumours and did not exhibit superior effector functions compared to the wild-type counterparts [87], which shows that TOX is necessary for TEX survival [102] and exemplifies the diverging regulatory networks underlying different exhaustion modules.

Stemness sustains response in the face of exhaustion

Founding and upkeep of tissues and cellular cohorts are routinely overseen by precursors with regenerative and stem-like attributes, and TEX are no exception. Despite the distinct exhaustion-associated epigenetic scars, an extensive and still expanding body of studies has firmly established a distinguishable subgroup of TEX with reserves for longevity, self-renewal, and proliferation transcending those of the rest, which is correspondingly named ‘precursor exhausted’ or ‘progenitor exhausted’ T cells (TPEX) but also sometimes referred to as ‘stem-like’ and ‘memory-like’ cells [16, 76, 89, 103, 105–110]. The relevance of TPEX in cancer and immunotherapy was presaged by cornerstone works in chronic viral infections [105, 111, 112], and notably a PD-1+CXCR5+CD8+ T cell population possessed a gene signature resembling memory precursor cells and haematopoietic stem cell progenitors, and proliferative bursts after PD-1 blockade while differentiating into more terminally differentiated effector-like progenies [105], although TPEX are typically lacking in cytotoxicity themselves [17]. The existence and behaviour of such cells have been then substantiated in lung cancer [110] and melanomas [76, 90], and ablation of these cells dampened efficacy of checkpoint blockade. Further studies have validated significant post-treatment intra-tumoural accumulation of TPEX exclusively in ICB responders, where lineage tracking analyses credited the cell population increase to the composite effect of local expansion of pre-existing tumour-specific clonotypes and likely an influx of extratumoural T cells, in light of the novel TCR clonotypes not present within the tumour prior to therapy [74, 107, 113].

Unsurprisingly, TPEX may co-express exhaustion (e.g., TOX and PD-1), memory (e.g., EOMES, SLAMF6 [Ly108 in mice], BCL6, ID3, and IL7R[CD127]), and naïve-like cell markers (e.g., CCR7 and CD62L) [84, 105, 114]. TPEX differentiation is governed by an expansive set of TFs such as FOXO1 [115, 116], BCL6 [114], MYB [117], BACH2 [118], and HMGB2 [119]. Notably, T cell factor 1 (TCF1, encoded by Tcf7) has emerged as a key TF that dependably defines TPEX [76, 84, 108, 109]. TCF1 is a well-known enactor of Wnt-β-catenin signals and assumes a myriad of roles in T cell development and maturation pending the precise circumstance [120, 121]. At the post-antigen encounter bifurcating point of CD8+ T cell fate, TCF1 conspicuously steer differentiation of effector-phase lymphocytes towards the stem-like endpoints as opposed to short-lived effectors, giving rise to TCM in acute infection [22, 122] and TPEX in chronic infection and tumour models [29, 92, 114, 123–125], suggesting the transcriptional schemes that instil stemness in these two cell populations are, at the very least, partially overlapping [14, 31, 113, 126]. On the contrary, as TCF-1 suppresses TGF-β-induced CD103 expression [77], TRM are known to be TCF1− [70, 76, 77], despite displaying a stem-like phenotype comparable to that observed in TCM and TPEX. Moreover, involvement of TCF1 in TPEX generation is likely redundant and relies on coordinated changes in a set of additional factors [125], where Tcf7 knockout did not significantly alter the abundance of TPEX TIL [76]. On the other hand, TCF1 has been demonstrated to be indispensable for the maintenance of the TPEX phenotype and arbitrates tumour control and response to ICB as well as cancer vaccination, with clear superiority of the TCF1+CD8+ T cell population over the TCF1− counterparts in these regards [76, 90, 109, 127]. In fact, a recent study has shown that TCF1 is required for optimal priming of tumour-specific CD8+ T cells and ICB efficacy in the context of poorly but not highly immunogenic tumours [124], resembling the critical role of TCF1 in ‘pre-programming’ the chromatin landscape of TCM for proper upregulation of the necessary cell cycle, DNA replication and glycolysis-related genes during a recall response [122].

Nevertheless, closer examination of TPEX has shown that TCF1 alone is insufficient to demarcate the subsets of biological significance contained within the heterogenous cell population [103]. A recent study conducted in the murine LCMV infection model unveiled that CD62L+ TPEX, whose development relies on MYB, are transcriptionally distinct and functionally superior to the CD62L ones, and bring forth the proliferative burst following PD-1 blockade[117]. Cells with a comparable transcriptomic profile have been identified in CD8+ CAR-T cells responding to B-cell acute lymphoblastic leukaemia, with FOXP1 being a newly identified hub TF that orchestrates stemness and anti-tumour response, although the equivalent to this subpopulation fortified with stemness was not readily evident in the cells infiltrating solid tumours in the same study[149]. Similarly, TCF1+ TPEX with circulating capacities and greater proliferative potentials are found to be associated with an SLAMF6+ as opposed to SLAMF6−phenotype in a murine lung adenocarcinoma model[163].

En route to terminal exhaustion

Tumour-specific TPEX on the ground, along with other stem-like populations, eventually embark on the forced march in the direction of terminal exhaustion (Fig. 1A), at which point irrecoverable loss of intrinsic and therapeutically inducible anti-tumour activity manifests. Although terminally exhausted CD8+ T cells (TTEX) exuberantly express IFNG, PRF1 and GZMB transcripts [4, 18], diminished polyfunctionality, survival, and expanding capacities fundamentally restrict the cumulative anti-tumoural potential of individual TTEX, which are not amenable to ICB reinvigoration despite plentiful expression of checkpoint molecules such as PD-1 and TIM-3 [88, 109, 113]. Markers for TTEX also notably include CD39 (ENTPD1) [4, 90, 113, 126], an ectonucleotidase that, in conjunction with CD73, potently generates extracellular adenosine, which is known to inhibit T cell signalling cascades [128–130]. Accordingly, Vignali et al. have recently shown that not only do TTEX take on a powerless stance against tumour cells, but they also exert immunosuppressive effects comparable to those of Foxp3+ regulatory T cells (TREG) isolated from the same tumour environment, primarily through hypoxia-driven enhancement of CD39 density and activity [131], in accordance with the benefits observed with exploratory usage of CD39/CD73 monoclonal antibodies [132] and dual inhibition of CD39 and TIM3 [90] in mouse tumour models. Contrarily, the authors did not observe significant alterations in tumour growths or TTEX-mediated immune suppression with germline deletion of or neutralising antibody administration against IL-10 [131], a pleiotropic cytokine with well-recognised anti-inflammatory and immunomodulatory functions whose involvement in cancers is obscured by the discordant findings in available studies [133]. Interestingly, an engineered IL-10-Fc fusion protein actualised TPEX-independent re-expansion and cytotoxic function revitalisation of TTEX through fostering mitochondrial pyruvate carrier-dependent oxidative phosphorylation [134], echoing other pre-clinical [135] and clinical [136, 137] studies. However, the following phase II trials combining PEGylated IL-10 and anti-PD-1 antibodies led to doubling of treatment discontinuation rate due to adverse events while bringing no added survival benefits in metastatic non-small cell lung cancer patients [138]. Taken together, these findings highlight the fact that, in addition to being functionally subpar, TTEX can potentially exert suppressive actions owing to susceptibility to the various TME elements, and that therapeutic strategies alternative to ICB, especially those pertaining to reprogramming T cell metabolism, could potentially exploit the remaining, albeit very limited, plasticity of TTEX, though how they may best synergize with other modalities of immunotherapy and accurately target the intended cells is to be explored.

Fig. 1 Outlining CD8+ T cell evolution in cancer. (A) On the way to terminally differentiated states, naïve CD8+ T cells in cancer move through a meshwork of transcriptomically distinct phenotypes. The cells may stroll down the exhausted (top) or memory (bottom) thoroughfare, though memory cells can give rise to exhausted cells after acquiring the epigenetic imprints and the TRM branch has clear transcriptional idiosyncrasies. In general terms, progression through either lane sees the waning of stem-like features and reprogrammability by immunotherapy and eventual fate convergence at the TTEX terminus. TEXEFF and TEMRA are lineage-wise juxtaposed with TPEX but infused with heightened effector capacities. (B) Subsets of TEX are identifiable by the expression of an assortment of TFs and surface proteins. TPEX are vital to maintaining the exhausted T cell populations due to their stem-like features and capabilities to self-renew, as indicated by TCF1 expression, whereas TOX marks the inability of exhausted cells to fully reconstitute the memory or effector functions. The quiescent TPEX1 subset is distinguished from the mobilised ones by SLAMF6 and CD69 expression profiles. The activated state of TPEX2 is illustrated by the acquisition of the proliferative marker MKI67 and effector molecules IFN-γ and TNF-α, whose expression plateaus in TINT before returning to low levels in TTEX. In addition to escalation of immune checkpoint molecules (e.g., PD-1), TTEX also express terminal exhaustion makers (e.g., CD39 and TIM-3). TEXEFF may form in place of TTEX only under certain circumstances such as TH-derived IL-21 induction. TEX differentiation is under the oversight of an extensive, tightly regulated TF network, as shown in the figure. Notably, many of the TFs maintaining the TPEX population are implicated in memory formation, and those propelling their differentiation support the effector cells during acute infection.

Meanwhile, progression from TPEX to TTEX entails a sophisticated succession of events subject to an array of cell-intrinsic and extrinsic modifiers and thus markedly variable in pace, but generally aligns with the alterations in expression levels of the master regulators, namely a hierarchical loss of TCF1-instituted stemness and culmination of TOX-associated epigenetic imprinting, which foreshadow the downstream transcriptional and functional changes [88, 102]. Though direct transitioning from TPEX to TTEX has been observed [139], TPEX differentiation into a metabolically rewired and actively proliferating intermediate-exhausted phenotype (TINT), marked by a Tim3+CD101− phenotype or CX3CR1 expression in chronic infections [17, 139, 140], proves to be a pre-requisite step to liberate the full anti-tumour potential and ICB responsiveness of TPEX [103, 140–143], since TPEX are mostly quiescent by default, as attested by low expression of cell cycling genes such as MKI67 [17]. This is validated by the latest advances, where toning down Ikzf1 (encoding IKAROS, which suppresses TCF1) has successfully retarded TPEX-to-TINT differentiation, but failed to evoke added antitumour effects [142]. Admittedly, the transitory TEX populations were evident in earlier TME profiling studies [19, 32, 89, 90], but their structured categorization was pioneered by Beltra et al., where, using Ly108 (a proxy marker for TCF1) and CD69, they have distinguished the interconverting quiescent (TPEX1, Ly108+CD69+) and proliferating (TPEX2, Ly108+CD69−) subsets of TPEX, and established the developmental trajectory from TPEX2 to Ly108−CD69− TINT and ultimately Ly108−CD69+ TTEX [103], thus completing the TPEX1 ➜ TPEX2 ➜ TINT ➜ TTEX paradigm that was consolidated by succeeding studies [142, 144–146] (Fig. 1B). Increasing evidence suggests that the TPEX2-to-TINT junction harbours a critical epigenetic, transcriptional and metabolic checkpoint, whose regulation incorporates inputs from activation of the mTOR pathway [142], which serves as a control panel integrating cellular metabolism sensor signals [147], and a range of TFs, including T-bet [103, 142, 148], BATF [148], KLF2 [149], ETS1 [142], and STAT5 [150]. In fact, augmentation of Stat5 activity by employing an orthogonal IL-2:IL2Rβ pair system in established TEX cells not only stimulated TINT formation, especially when combined with PD-L1 blockade, but also improved their durability and effector functions in the face of persistent antigen stimulation, and suppressed differentiation to TTEX [150].

Indeed, TINT may still bear therapeutically accessible developmental pliability and effector potential. A growing body of studies has shed light onto an alternative differentiation path from the TINT waypoint to an effector-like exhausted (TEXEFF) population that is inducible by IL-21-producing CD4+ helper T cells (TH) [139], TF ZEB2 [144], and lower TCR avidity [81, 146], and lineage-wise juxtaposed with TTEX but possesses strong effector or NK cell characteristics [81, 139, 146]. Multiple lines of evidence derived from murine chronic infection models are in support of this bifurcating model placing TINT at the branch point, including the in silico predictions based on pseudotime and RNA velocity trajectory analyses, retained phenotypic plasticity in TINT but not TEXEFF or TTEX upon adoptive transfer, and shared open chromatin regions between TINT with either TEXEFF or TTEX and the paucity thereof between TEXEFF and TTEX [81, 139, 146]. This novel model is of great therapeutic relevance, as it provides the theoretical foundation for a window of opportunity, perhaps the last one before the end-stage epigenetic ossification takes place, to expand the aggregate effector activity by diverting TINT towards the TEXEFF fate in lieu of TTEX [151].

To complicate matters even further, concurrent ‘non-TPEX-origin’ trajectories to TTEX progressing through memory subsets have been described [4, 70, 72, 74, 144, 152], which are generally organised into two interlaced paths marked by the resident-versus-circulating duality of memory (Fig. 1A). In a pan-cancer TIL atlas constructed from scRNA-seq data from 316 patients across 21 cancer types, Zheng et al. projected that CD8+ TN could ultimately develop into either TEX or TEMRA [4], concordant with recent identification of a non-TEX ZNF683high TEFF/TEM endpoint that was accentuated in marrow-infiltrating CD8+ T cells in Richter syndrome responding to PD-1 blockade [152]. Along the path to TEX, TN first progressed to IL7R+ TMEM (TCM/TSCM) and then split into the GZMK+ TEM and ZNF683+CXCR6+ TRM branches before uniting at the GZMK+ TEX and, finally, TTEX fate [4]. A similar scheme was outlined in an NSCLC dataset, involving progression to TTEX (CD8-LAYN) through a transitional population (CD8-GZMH) from circulating (CD8-KFL2/CD8-GZMK) and tissue-resident (CD8-XCL1) precursors, where the TRM population is deemed the main source of the more differentiated tumour antigen-specific T cells based on TCR sharing [72] – a clonal predilection that was also seen in ovarian [70] and neoadjuvant ICB-treated oral cancers [74]. Taken together, suffice it to say, notwithstanding the concrete accomplishments in the nuanced dissection of the phenotypes, current models may still merit refinement and reconciliation for an unequivocal representation of CD8+ TIL development and evolution, which is made particularly challenging by the confounding qualities unique to chronic antigen stimulation and TME, the logistical and technical constraints, and the taxonomical dilemmas for the betwixt and between cell populations.

Navigating the haemolymphatics and TME: a spatial odyssey

The relevance of tumour-specific CD8+ T cell phenotypes is nullified if detached from the position coordinates, given the contact-dependent nature of their tumoricidal weaponries. Indeed, the quantity and spatial distribution of CD8+ TILs demonstrated drastic variations across the cancer types, anatomical sites, and lesion classifications (i.e., primary, recurrent, or metastatic) [2, 4]. This observation has prompted development of Immunoscore, a histological type-agnostic grading system quantifying CD3+ and CD8+ lymphocyte densities in the tumour core and the invasive margin that has shown prognostic values in colorectal and other cancers [2, 153–156], effectively categorising tumours into immune infiltration-based ‘immunotypes’, namely the heavily infiltrated ‘hot’, the infiltration-devoid ‘cold’, and, between these two extremes, the uniformly poorly infiltrated ‘immunosuppressed’, and the ‘excluded’ tumours where infiltrates are limited to the invasive margin [155]. Importantly, the immunotypes cannot be explicated by tumour cell antigenicity alone and are in fact telltale snapshots that mark the culmination of the long march of CD8+ T cells as they migrate through different circulatory compartments, penetrate multiple barriers, and persevere in spite of suppressive environments, to complete the larger cancer-immunity cycle [157]. Along the journey, CD8+ T cells adjust the balance of tissue anchoring and egress factors to facilitate or restrain translocation, perform tissue-specific adaptive manoeuvres, and pass through several key anatomical and microenvironmental locales that profoundly shape their dynamics (Fig. 2), leading to reverberations in the intratumoural CD8+ T cell landscape.

Fig. 2 Critical anatomical and microenvironmental waypoints dictating success of CD8+ T cell infiltration. (A) TDLNs are the ideal venue for tumour antigen-bearing migratory DCs from the TME to condition the TH and CD8+ T cells. The migratory DCs also pass on the antigens and TME cues to their resident counterparts. With provision of the primary, costimulatory, and cytokine signals by the DCs and TH sans the inhibitory TME elements, CD8+ T cells have the privilege of remaining in the stem-like states and serving as a reservoir of tumour-repressive cells. Establishment of metastases in the LNs demolishes the supportive context for these population-sustaining CD8+ T cells. (B) Tumour-associated vascular endothelium is a major barrier against T cell infiltration. Endothelial expression of FasL can precipitate direct CD8+ T cell death. Aberrant adhesion molecule expression secondary to VEGF-induced endothelial cell anergy renders it impregnable to CD8+ T cells. Tumour-associated high endothelial venules are important sites for CD8+ T cell extravasation and aggregation. (C) CAFs orchestrate the tumour-associated stroma and mediate T cell exclusion in a multitude of ways, as illustrated. The APC niches and TLSs are on-site powerhouses that harbour stem-like CD8+ T cells and, by safeguarding their survival, greatly amplifies anti-tumour immunity. Conversion to the more terminally differentiated phenotypes ensues the longer the dwell time and the closer the distance to the tumour cells, which are known to foment an immunosuppressive aura.

Tumour-specific CD8+ T cells gear up in TDLNs

The conventional school of oncology often view TDLNs as receptables forming the catchment for metastatic seeding, which is predisposed by the architectural and functional deviations from the non-draining nodes provoked by tumour-derived lymph-borne factors [158]. Removal of uninvolved TDLNs, however, failed to improve outcomes in preclinical models or cancer patients [159–161]. In this day and age, the significance of TDLNs as a nexus between the cancer and immune cell ends of the tug-of-war has been brought back to attention and reinforced, and their role in facilitating generation of CD8+ TILs reaffirmed, for the key window for antigen presentation and T cell priming arises as tumour antigens, T lymphocytes, and dendritic cells (DCs) converge in the lymphatic endothelial cell (LEC)-lined and macrophage-interspersed subscapular sinuses (SCS) of TDLNs [158, 162]. Current evidence suggests that CCR7-expressing type I conventional DCs (cDC1s) migrated from the TME are the main DC subset that internalise and transport tumour antigens in large quantities and potently prime CD8+ T cells through MHC-I-mediated cross-presentation or cross-dressing (direct transfer of peptide-MHC-I complex) [162–168] and CD4+ T cells through MHC-II-mediated direct presentation, which reciprocally augment the immunostimulatory proficiency of DCs [169]. Meanwhile, the TME IFN-I-induced ISG+ cDC2s also demonstrated capability to activate CD8+ T cells by cross-dressing in the absence of cDC1s [170]. Once arrived at the TDLN, the migratory DCs may in turn transfer tumour antigen to their resident counterparts to prepare the inbuilt DC terrain for CD8+ T priming [168, 171], where the DC status across the tissue origin and the LN may also be synchronised with co-transfer of contextual cues [172].

Given their nurturing multilayered cellular infrastructure and strategic anatomical locations, TDLNs are naturally the reservoirs of tumour-specific CD8+ TILs. An abundance of studies have provided evidence of CD8+ T cell transmigration from TDLNs to the tumour [14, 15, 141, 159, 163, 173–176] and vice versa [15, 177], as well as enrichment of tumour-reactive CD8+ clonotypes in TDLNs [175, 176, 178]. Unencumbered by the stress from persistent antigen stimulation and TME factors, activated tumour-specific CD8+ T cells in TDLNs are typically found in the minimally exhausted TPEX or TPEX-like states [79, 117, 141, 163, 173, 174, 178, 179], whereas those TILs clonally related to them predominantly display the TTEX phenotypes [141, 173, 178]. In fact, expansion of pre-existing or de novo LN-dwelling stem-like populations is vital to ICB response [14, 105, 175, 176, 180] (Fig. 3A) and potentially accountable for a greater share of efficacy than those circulating or residing in the TME, as surgical removal of TDLNs [14, 181], co-administration of FTY720, an inhibitor of T cell egress from lymphoid organs [175, 176, 181], was sufficient to negate the antitumour effects of ICB, and targeted delivery of ICB monoclonal antibodies to the TDLNs eclipsed systemic therapy in terms of efficacy and permitted dose sparing [179]. Furthermore, studies have consistently shown that the responses of TDLNs to ICB and the integrity of TLDNs as an immune reservoir and line of defence in general can be profoundly undermined by presence of metastases [141, 182–185]. In both melanoma murine models and human patients, LN metastases precipitated an altered immune contexture involving IFN-II-associated accumulation of regulatory T cells (TREGs) and PD-L1+ DCs that suppressed CD8+ T cells [183, 184]. These tolerogenic cells were also observed in LNs with HNSCC metastasis and, along with naïve/quiescent (CD45ROloPD-1loTCF-1hi) CD4+ T cells, formed the immunosuppressive niches encircling TPEX and TINT post-ICB [141]. Overall, these evidences offered an additional explanation to the prognostic values of TDLN statuses from the perspective of CD8+ T cell anti-tumour immunity, revealed the underappreciated role of TDLN statuses in predicting the response to ICB, and conceptualised the combination of ICB with agents targeting LN metastases, the latter of which, however, are yet to be developed.

Fig. 3 Modifying CD8+ T response in cancer. (A) Immune checkpoint blockade radically changes the CD8+ T landscape via mobilisation of the stem-like populations, which primarily occurs in the company of supportive cells in the TDLNs and microenvironmental niches. Cancer cell death as a result of amplified response fosters a self-amplifying cycle owing to tumour antigen release and subsequent increased uptake and priming by APCs. ICBs can simultaneously stimulate TRM, which contributes to increased tumour killing and long-lasting immunosurveillance that deters recurrence and metastasis. (B) In addition to the conventional steps implicated in adoptive cell therapies (lymphocyte procurement, isolation, activation and expansion, pre-infusion lymphodepletion and post-infusion IL-2 administration), there have been multiple strategies in the phases of ex vivo manipulation and in vivo augmentation (marked with plus signs) to maximise the utility of transferred cells. A deeper understanding of the transcriptional, epigenetic, and metabolic controls of CD8+ T phenotypes will shed light on novel ways to engineer cells for the desirable attributes.

Overcoming the vascular endothelial barrier

Following potentiation of tumour-specific CD8+ T cells in the TDLNs, an endurance run through systemic circulation, tissue environment, and microvasculature awaits before they are able to reach the designated destination in the centre of tumour. Execution of such an extended process that requires extreme precision relies on coordination and fine-tuning of various homeostatic control systems. After priming, exit from the LNs is classically conducted with upregulation of S1PR1 in the context of high concentration of S1P in efferent lymphatics and synchronous curtailment of CCR7 and CD69 [6, 186], whereas sympathetic neural inputs typically promote retention of T cells in the LNs [187, 188]. Intact chemotactic systems are then a prerequisite for tumour homing, which include the CCR5-CCL5, CXCR3-CXCL9/CXCL10/CXCL11, CXCR5-CXCL13, CX3CR1-CX3CL1, and CXCR6-CXCL16 axes for CD8+ T cells [105, 109, 139, 189–194], where the transition from TPEX to TINT/TTEX may be accompanied by specific changes in expression of chemokine receptors [139, 177, 191]. Conversely, the elaborate interactions can be sabotaged or manipulated by solid tumours to diminish the driving force for cytotoxic T cell migration while fostering preferential recruitment of suppressive immune cells including TREGs, myeloid-derived suppressor cells (MDSCs), and tumour-associated macrophages (TAMs) and neutrophils (TANs) [189, 192]. The directionality of chemoattractant concentration gradient, which steers the CD8+ T cell traffic, also bears obvious significance as, for instance, the interplay between CXCR4+ TEFF and tumour-associated lymphatic vessel-derived CXCL12 resulted in marginalisation and egress of TILs, which undermines tumour control and therapeutic response [177].

Before CD8+ T cells could set foot on the core of the tumour, they can be repulsed by multiple chemical, physical, and cellular ramparts, and the tumour vasculature represents the first tumour-orchestrated line of defence that must be surmounted. In acute inflammation, leukocyte extravasation typically follows a multi-step progression, where friction for arresting cell locomotion is jointly supplied by selectins and adhesion molecules such as ICAMs and VCAM-1. Tumours resort to formation of blood vessels (termed ‘neo-angiogenesis’), which is stimulated by mechanical strain, hypoxia, and angiogenic molecules, with the VEGF family (VEGFA - F) being the most prominent, to fulfill the metabolic demands for neoplastic growths [195–197]. VEGF has the ability to directly influence immune cells, promoting development of TREGs, M2-macrophags, and MDSCs, impairing DC maturation and T cell development, and inducing CD8+ TIL exhaustion [195, 198–201]. When faced with relentless malignancy-driven bombardment by VEGF and other angiogenic factors, endothelial cells lining the tumour-associated blood vessels are prevented from activation by pro-inflammatory cytokines and conspicuously deviate from those in inflammation in terms of surface protein expression. Differentially expressed by neoangiogenic endothelium are immune checkpoint molecules [202, 203], FasL that selectively mediate CD8+ T cell demise [204], and, importantly, fewer adhesion molecules [205, 206], referred to as ‘endothelial cell anergy’, thereby veiling the portal of entry for tumour-specific CD8+ T cells. These observations serve as the mechanistic underpinning for combining anti-angiogenic agents with ICBs [194, 199, 201, 204, 207], where clinical trials have verified additive if not synergistic effects across several cancer types [208–213], which may be seen regardless of the intra-tumoural immune checkpoint molecule expression status [208, 211]. Notably, recent advances have demonstrated endothelial cells comprising the post-capillary venule (PCV)-derived MECA-79+ tumour-associated high endothelial venules (TA-HEV) as major breach sites for CD8+ T cells extravasation at baseline and in anti-CTLA-4 (+/- anti-PD-1) therapy, and increased number and maturation of these endothelial cells ushered a higher percentage of stem-like (SMALF6+) CD8+ TILs [214]. In preclinical models, anti-VEGFR2, anti-PD-L1 and LTβRAg triple therapy were sufficient to induce differentiation of PCVs into TA-HEVs that indeed facilitated lymphocyte infiltration and TPEX accumulation [215, 216].

Cancer-associated fibroblasts at the crux of CD8+ T-excluding and suppressing stroma

The tumour-associated stroma, apart from requitting the cancer-derived factors with direct facilitative and prohibitive influences on neoplastic cell-led tumour progression and metastatic transition, and thus holding cardinal non-immune-related biological and prognostic implications [196, 217–219], lies in between the extravasated CD8+ T cells and the nest of tumour cells, and contains various cellular and inanimate components with shielding effects. Being one of the most abundant and functionally significant constituents of tumour stroma, cancer-associated fibroblasts (CAFs) are evidently discernible from normal quiescent fibroblasts [218, 220, 221], commonly arise from co-option of resident fibroblasts by mechanical stress and cancer cell-secrete chemokines and growth factors (e.g., TGF-β, IL-1, IL-6, and PDGF), but are otherwise of remarkable plasticity (i.e., reactivity to external cues) and heterogeneity in origins and phenotypes and across tumour/tissue types, for which a unanimous classification system is lacking despite tentative, crude categorisation into myofibroblastic (myoCAFs, typically dependent on TGF-β for differentiation and ECM-associated genes/αSMAhigh), inflammatory (iCAFs, IL-1-dependent and IL-6/CXCL12high), and antigen-presenting CAFs (apCAFs, HLA-DR/MHC-IIhigh) [219–226].

Transcriptomic analyses have established the inverse correlations between myoCAF-associated signatures and abundance of CD8+ T cells as well as immunotherapy efficacy [219, 227–229]. Integration of spatial information allowed pinpointing of several myoCAF subsets in particular that mediate T cell repression and exclusion predominantly by deposition of extracellular matrix (ECM, a known trigger of CD8+ T cell exhaustion in cancer [230] and impediment to lymphocyte locomotion when densely packed or mal-aligned [231, 232]), as well as TGF-β secretion and interacting with other suppressive cell populations [221, 222, 227, 228, 233–236]. Costa et al. are among the first groups to portray myoCAFs at higher resolutions, where, using six fibroblast markers, they ascertained one particular myoCAF subset that tends to cluster near epithelial tumour cells in TNBCs and attracted, maintained, and differentiation into CD25highFOXP3high TREGs with augmented suppressive effects on CD8+ T cells [234]. Further deciphering endeavours followed thereafter. For example, in KPR mouse pancreatic adenocarcinomas, TGF-β-signalling-dependent LRRC15+ myoCAFs are shown to be in close proximity of and capable of suppressing CD8+ T cells [222]. In early- and advanced-stage lung cancers, MYH11+αSMA+ and FAP+αSMA+ myoCAFs have been respectively identified to obstruct T cell contact with tumour cells, albeit in different ways, where the former form a monolayer of elongated cells enveloping the tumour parenchyma and deposit type IV collagen fibres, and the latter are organised into patches or multiple layers and collagen XI and XII-producing instead [221].

In contrast, CAFs exhibiting an inflammatory or immune modulatory phenotype sculpt the immune cell landscape via extensive ligand-receptor interactions [224, 237]. CAF-emanated IL-6 recruits FOXP3+ TILs [235], invokes CD73 expression in γδTREGs [130], and induces differentiation of TME monocytes into MDSCs through STAT3 signalling [238]. Even though CAF production of CXCL12 can attract CD8+ T cells in infiltrated tumours [193], it oftentimes culminates in T cell exclusion [239, 240]. This could be the combinatory result of CD8+ T cells being misdirected towards the tumour margin [239–241], the paradoxical repelling effects of CXCL12 at high concentrations [242], and the CXCR4-CXCL12 apparatus-orchestrated CAF crosstalk with TREGs [234], SPP1+ TAMs [243], and other myeloid populations [244]. Moreover, Ma et al. have computationally derived from harmonised scRNA and ST data a multitude of ligand-receptor interactions through which iCAF can directly corrupt CD8+ T cell robustness [224]. Notably, the LGALS1-PTPRC interaction is among the most frequently seen on ST slices, which triggers NFAT signalling and thus CD8+ T cell exhaustion [224]. On the other hand, apCAFs may render anergic or convert naïve CD4+ T cells to TREGs with antigen-specific MHC-II-TCR crosslinking void of backing from co-stimulatory molecules [226, 245], and direct antigen-dependent interaction with CAFs can precipitate PD-L2 and FasL-mediated lethality to the antigen-specific CD8+ T cells [246]. That being said, in lung cancers, apCAFs are found to activate and protect CD4+ T cells from apoptosis and consequently tumour-suppressive rather than permissive [247]. Additionally, non-canonical markers have also proven to be useful for setting apart non-ternary CAF subsets with immunomodulatory effects. A distinct cluster of CAFs has been discovered in HNSCC that sequester TPEX (TCF1+GZMK+) by enhanced MHC-I and CXCLs expressions and impede their effector transformation through leveraging galectin-9 [240]. In pancreatic ductal adenomas (PDACs), CD105 effectively partitioned CAFs into two fractions displaying opposite correlations with immune cell subpopulations, with the CD105− subsets being positively associated with proliferation of the CD8+ subsets, whilst the CD105+ counterparts had a negative association [248]. Specifically, the CD105−MHCII+CD74+ CAFs were the sole mesenchymal subset securing a positive correlation with antigen-experienced but non-terminally exhausted CD8+ TILs [248].

Considering the myriad of ways CD8+ T cells are obstructed and subjugated, therapies targeting CAFs have been extensively investigated, and combination with therapeutic strategies carrying direct empowering effects on CD8+ T cells (e.g., ICBs and CAR-T therapy) attempted as a natural course of action for the prospect of “infiltrate and eliminate“ [233, 239, 242]. As an embodiment of this approach, antecedent treatment with CAR-T targeting FAP+ CAFs in a recent study on murine PDAC models dismantled the desmoplastic stroma and dispersed the associated immunosuppressive environment, allowing full engagement of ICB-reprogrammable endogenous CD8+ T cells and CAR-T cells targeting tumour-associated antigen (Meso-CAR-T) with tumour cells [249]. Nonetheless, given the phenotypic multiplicity of CAFs and their restraining effects on tumours [226, 247, 250, 251], indiscriminate ablation of CAFs may accelerate cancer progression even with increased CD8+ T cell infiltration [250], hence the imperative to selectively deplete the reprehensible CAF subsets for clear-cut clinical benefits.

Seeking sanctuary in the immune-permissive microenvironmental enclaves

Once advanced to the immediate vicinity of tumour cells, CD8+ TILs plunge into the hypoxic, acidified, adenosine and potassium ion-imbued, and nutrient-deficient or perturbed quagmire, which overwhelmingly favours CD8+ T dysfunction and sealing of the exhaustion fate [252, 253]. In accordance with this, intra- or peri-tumoural TPEX are rarely found flanked by tumour cells unbuffered, but tend to congregate in spatial niches conducive for population maintenance and effector differentiation [76, 106, 143, 174, 190, 191, 216, 254–256], and in some cancer types, the density and quality of these structures may set patients with favourable outcomes apart from those with poor prognosis [106, 257], and ICB responders from non-responders in the scenario of intact T cell priming in TDLNs and unhindered infiltration [143]. Cells with both antigen-presenting and immunomodulatory capabilities, especially DCs, are almost invariably implicated in the organisation of these CD8+ T-accommodating alcoves [174, 190, 191, 257–259]. DCs close the distance with the inbound CD8+ T cells through specific interactions between chemokines and their receptors (e.g., CXCL16-CXCR6 [191] and CXCL9/CXCL10-CXCR3 [190, 194, 257]), granting the primary and co-stimulatory licences [169, 174, 255, 260], and unleash cytokines crucial for survival and induction of effector functions, such as IL-12 [261] and IL-15 [143, 191]. Prostaglandin E2 [262] and immune checkpoint molecules like TIM-3 [258] and PD-L1 [259] are notable for interfering with the DC-CD8+ TIL communication, thus explaining at least part of the benefits seen in respective therapies. Spatial profiling studies have also substantiated that DCs can complex with the CD4+ TH subsets they primed to form dyadic powerhouses that exert strengthened chemoattractant and invigorating influences on CD8+ T cells [143, 169, 263].

Tertiary lymphoid structures (TLSs) are the most sophisticated form of ectopic lymphoid tissues that can be found in tumours. Representing the pinnacle of immune cell reciprocity within the TME, TLSs are structurally less organised (i.e., unencapsulated and variable in T and B cell compartmentalisation) but cellular composition-wise reminiscent of SLOs, where each type of cells undertake corresponding roles that ultimately contribute to a brisk and self-replenishing local adaptive response [264], as tumours with TLSs had denser and less dysfunctional intra-tumoural T cell infiltrates [254, 265–267]. Like in SLOs, presence of HEVs [216, 268] and a stromal network primarily consisting of follicular reticular cells (FRCs) [264] in TLSs secures the microanatomical space for lymphocyte passage and residence. The TLS-defining CD20+ B cells can be intermingled with T cells or gather in follicles with or without germinal centres, and nurtured by the CD4+ follicular helper or CD21+ follicular dendritic cells [264]. In addition to the canonical role of producing antibodies, TLS B cell subsets have been reported to be capable of energizing T lymphocytes by antigen presentation and cytokine secretion [266, 269–271]. In the meantime, the CD4+ TH and DC duo have been found enriched in TLSs, predominantly in the T cell zones [254, 263], and so have tumour-reactive and stem-like CD8+ T cells [76, 106, 256, 265, 272], which integrate the inputs from the neighbouring immune cells and proceed to tackle the tumour cells.

TLSs are generally associated with improved survival outcomes and immunotherapy responses [265, 266, 269, 270], and yet, on scrutinisation, the localisation and maturity level of TLSs wield pivotal influences [267, 273], where extra-tumoural positioning and immaturity may underpin the negative prognostic impacts of TLSs in clear cell renal cell carcinoma [273, 274]. TLS formation beholds a choreography of lymphocytes, myeloid cells and mesenchymal cells under the guidance of molecular factors including lymphoid chemokines (e.g., CXCL13, CCL19, and CCL21), LTs, IFN-Is, TNFs, IL-17, many of which have been appropriated to experimentally induce TLSs in murine models [264]. CXCL13+CD8+ T cells have been described, were determined to be tumour-reactive and predictive of ICB response [275], and indeed correlated with TLS presence [272, 276], though it was reported that their dysfunctional states and contribution to an immunosuppressive milieu might ultimately lead to unfavourable outcomes [276].

Perspectives

The notion that not all CD8+ TILs are created equal stands truer than ever. An outpouring of multi-dimensional and high-resolution data over the past few years spotlighted the stem-like exhausted and memory cells as the subsets of the highest tumour-suppressive yield at baseline and upon therapeutic intervention. Their transcriptomic and epigenetic properties are being characterised and phylogenetics elucidated, to a level of certainty, precision, and scale previously unfathomable, revealing invaluable insights into the promising biomarkers for prognostication, subpopulations for successful adoptive transfer, and strategies for engineering CAR-T cells (Fig. 3B).

Innovative and painstaking iterative processes with state-of-the-art technologies paved the way for these ground-breaking discoveries. Recent implementation of in vivo sc-CRISPR screening to TFs concerning CD8+ T cell differentiation and exhaustion in cancer may have just constructed the most comprehensive TF directory for T cell fate to date [142]. Synergising available omics modalities represents an alternative tactic for new discoveries. Mapping and deconvolution algorithms are routinely applied to scRNA-seq and ST data to confer spatial coordinates to individual cells and deduce the cellular composition of each ST spot [5, 224, 236, 240]. Building on the previously known markers for tumour specificity, which are frequently also tokens of exhaustion (e.g., CD39, PD-1, TIM-3 and TOX) [4, 18, 68, 277], coupling of scRNA-seq, sc-TCR-seq, and TCR specificity testing data helped to fish out the tumour-reactive stem-like CD8+ T cells from the swarm of bystanders, which are otherwise difficult to tell apart due to transcriptomic similarity [18, 56, 127, 275, 278]. Disciplined application of these investigative tools to the matched longitudinal samples enabled a chronicle of the tumour-reactive clonotype dynamics in naturally occurring anti-tumour immunity and immunotherapies [18, 56, 275], laying down the ground truth against which computational inferences can be compared, and the methods refined. Furthermore, the recent invention of Zman-seq, which combines scRNA-seq with time-stamping by sequential injections of fluorescent anti-CD45 antibodies that selectively tag circulating immune cells but not those already infiltrated the tumour, allows cataloguing of transcriptomic states with different durations of TME residence and consequently deciphering of the temporal dynamics [279]. Much to the excitement of the academia and the medical community, the methodological revolution seems to have provided the necessary means to materialise the envisioned all-encompassing cell tree for CD8+ T cells in health and disease [7]. The much-anticipated nomenclatural reform, however, has lagged behind, and work still needs to be done to mend the gap between the newly acquired high-dimensional information and legacy observations from the pre-omics era. Besides, caution should be exercised when interpreting data from the viral models, due to the overlapping but nuanced phenotypes [56, 81, 84] and asynchronous pace of exhaustion [86] between the exhausted CD8+ T subsets in chronic viral infections and those in tumours.

That key steps of CD8+ T cell priming and maturation take place across anatomical locations outside of the tumour mandates a cross-the-body relay in parallel with the phenotypic evolution of tumour-specific CD8+ T cells, which is an extremely error-prone process. Any misstep could end up with flawed immunotypes that render tumour cells inaccessible to the tumouricidal arsenal of CD8+ T cells, which operate exclusively in close quarters. Conversely, drawing on the continually expanding mechanistic insights, each nucleating point of CD8+ T anti-tumour immunity, be it the TDLNs, APC-rich niches, or TLSs, may represent an opportunity for therapeutic amplification, and the vascular and stromal barriers for ablation, especially in the ‘excluded’ immunotype. Similarly, the phenotypic pliability of CD8+ T cells, whilst hijacked by TME factors for exhaustion induction, is a double-edged sword malleable to therapeutic honing in recognised and less obvious ways. In broader terms, CD8+ T cells are inscribed with marks of systemic immunological wellbeing, which is dictated by age, sex, hormone levels, antigen exposure history, and comorbidities of individuals, but also newly established determinants such as commensal microbiota. An elegant testament bolstering the linkage is the recent discovery of PD-1 blockade efficacy enhancement by gut L. johnsonii and C. sporogenes, which collaborate to convert tryptophan to IPA, a metabolite that promotes H3K27 acetylation of the super-enhancer region of Tcf7, thereby diverting CD8+ T cells towards differentiation into TPEX [280]. The impacts of systemic immune health factors on CD8+ T-mediated anti-tumour immunity are therefore also worthy of further investigation, from which individualised and easy-to-implement immune-boosting diet and lifestyle interventions can be devised.

In conclusion, CD8+ T cells are indispensable for executing adaptive antineoplastic response, as they are positioned at the converging point downstream of miscellaneous immunomodulatory pathways to administer the coup de grâce to tumorous cells by unleashing direct cytotoxicity. The vast phenotypic and spatial heterogeneity of CD8+ TILs are being unveiled as we venture forth into the age of omics. Expanding on the preceding efforts to activate, reprogramme, and facilitate the infiltration of tumour-specific CD8+ T cells, the first-of-its-kind FDA approval for TIL infusion therapy in melanoma has officially advanced the forefront of immeasurable possibilities into clinical practice [281]. Working towards a consensus ontogeny to synthesise the multimodal data and delving into the mechanistic underpinnings will help to maximise the yield of CD8+ TIL-based cancer therapies, ultimately translating into better outcomes for patients.

Acknowledgements

We appreciate all the valuable inputs from the colleagues in our laboratory. We also would like to thank Zhou He (College of Computer Science and Technology, Zhejiang University), Xuan Li (University of Bristol), Dr Chang Ge (School of Medicine, Zhejiang University), and Dr Jieqiong Chen (Shanghai Institute of Immunology, School of Medicine, Shanghai Jiao Tong University) for their contribution to this work. The figures in this manuscript were created with BioRender.com.

Author contributions

Conceptualization, Y.S., E.Y., S.W., Z.W., B.L., and Z.Y.; Writing – Original Draft, Y.S., E.Y., F.W., Y.X., and W.Z.; Writing – Review & Editing, Y.S., E.Y., S.W., Z.W., F.W., Y.X., W.Z., S.Z., H.M., S.C., and L.J.; Visualisation, Y.S, E.Y., S.W., F.W. and Y.X.; Supervision, E.Y., S.W., Z.W., B.L., and Z.Y.

Funding

This work was supported by National Natural Science Foundation of China (82273178) and Zhejiang Province Traditional Chinese Medicine Science and Technology Plan (2023ZR108).

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethical approval

This study did not involve the participation of human or animal subjects, and, therefore, was exempt from formal assessment by the ethics committee for clinical research of our centre.

Competing interests

The authors declare no competing interests.

Abbreviations

αSMA alpha smooth muscle actin

ACAT-seq Assay for Transposase Accessible Chromatin with high-throughput sequencing

AHR aryl hydrocarbon receptor

AP-1 activator protein 1

APCs antigen-presenting cells

BACH2 BTB and CNC homologue 2

BATF Basic Leucine Zipper ATF-Like Transcription Factor

BCL-6 B-Cell Lymphoma 6

BLIMP-1 B-lymphocyte-induced maturation protein 1

CAFs cancer-associated fibroblasts (myoCAFs – myofibroblastic CAFs; iCAFs – inflammatory CAFs; apCAFs – antigen-presenting CAFs)

CAR chimeric antigen receptor

CCL/R C-C motif chemokine ligand/receptor

cDC1/2s type I/II conventional dendritic cells

CRISPR clustered regularly interspaced short palindromic repeats

C. sporogenes Clostridium sporogenes

CTLA4 Cytotoxic T-Lymphocyte Associated Protein 4

CX3CL/R C-X3-C motif chemokine ligand/receptor

CXCL/R C-X-C motif ligand/receptor

DCs dendritic cells

ECM extracellular matrix

Egr1/2 early growth response 1/2

ENTPD1 ectonucleoside triphosphate diphosphohydrolase-1

EOMES Eomesodermin

FAP fibroblast activation protein

FasL Fas ligand

FOXO1 forkhead box protein O1

FOXP1/3 forkhead box protein P1/3

FRCs follicular reticular cells

GZMB/H/K granzyme B/H/K

H3K27 histone H3 lysine 27

Havcr2 Hepatitis A Virus Cellular Receptor 2

Hic1 hypermethylated in cancer 1

Hif1a hypoxia inducible factor 1 subunit alpha

HLA-DR human leukocyte antigen, DR isotype

HMGB2 high mobility group box 2

HNSCC head and neck squamous cell carcinoma

HOBIT homolog of Blimp-1 in T cells

ICAM intracellular adhesion molecule 1

ICB immune checkpoint blockade

ID2/3 inhibitor of DNA binding 2/3

IFN-I/II type I/II interferons

IFN-γ/IFNG interferon gamma

Ikzf1 IKAROS family zinc finger 1

IL interleukin

IL7R interleukin 7 receptor

IRF4 interferon regulatory factor 4

IPA indole-3-propionic acid

ISG interferon-stimulated genes

ITGAE integrin subunit alpha E

KLF Kruppel-like factors

Lag3 lymphocyte-activation gene 3

LAYN Layilin

LEC lymphatic endothelial cell

LGALS1 galectin 1

L. johnsonii Lactobacillus johnsonii

LRRC15 leucine rich repeat containing 15

LTβRAg lymphotoxin beta receptor agonist

LTs leukotrienes

MAPK mitogen-Activated Protein Kinase 1

MDSCs myeloid-derived suppressor cells

MEK also known as MAPKK (mitogen-activated protein kinase kinase)

MHC-I/II major histocompatibility complex I/II

MKI67 marker of proliferation Ki-67

mTOR mammalian target of rapamycin kinase

MYH11 myosin heavy chain 11

NFAT nuclear factor of activated T-cells

NK natural killer (cells)

NLT non-lymphoid tissue

NOTCH neurogenic locus notch homolog protein 1

Nr4a nuclear receptor subfamily 4 A

OVCAR-3 (NIH) ovarian carcinoma cell line 3

PCV post-capillary venule

PD-1 programmed death-1

PDACs pancreatic ductal adenomas

Pdcd1 programmed cell death 1

PDGF platelet-derived growth factor

PD-L1/2 programmed death-ligand 1

PRF1 perforin 1

PTPRC protein tyrosine phosphatase receptor type C

RUNX3 runt-related transcription factor 3

S1PR1 sphingosine 1-phosphate receptor-1

scRNA-seq single-cell RNA sequencing

SCS subscapular sinuses

SLAMF6 SLAM family member 6

SLOs secondary lymphoid organs

SPP1 secreted phosphoprotein 1

ST spatial transcriptomic

STAT signal transducer and activator of transcription

TA-HEV tumour-associated high endothelial venules

TAM/Ns tumour-associated macrophages/neutrophils

TCF1 transcription factor 1

TCM central memory cells

TCR-seq T cell receptor sequencing

TDLNs tumour-draining lymph nodes

TEFF effector CD8+ T cells

TEM effector memory cells

TEMRA effector memory re-expressing CD45RA (terminally differentiated effector memory) CD8+ T cells

TEX exhausted CD8+ T cells

TEXEFF effector-like exhausted

TFs transcription factors

TGF-β transforming growth factor beta

TH CD4+ helper T cells

TIGIT T cell immunoreceptor with Ig snd ITIM domains

TILs tumour infiltrating lymphocytes

TIM3 T cell immunoglobulin mucin 3

TINT intermediate-exhausted phenotype

TLSs tertiary lymphoid structures

TME tumour microenvironment

TMEM memory CD8+ T cells

TN naïve CD8+ T cells

TNF-α tumour necrosis factor alpha

TOX thymocyte selection-associated HMG box

TPEX progenitor exhausted T cells

TREG (CD4+) regulatory T cells

TRM tissue-resident memory T cells

TSCM stem cell memory T cells

TTEX terminally exhausted CD8+ T cells

WNT wingless-related integration site (signalling pathway)

VCAM vascular cell adhesion molecule

VEGF(R) vascular endothelial growth factor (receptor)

VIM vimentin

XCL1 X-C motif chemokine ligand 1

ZEB2 zinc finger E-box binding homeobox 2

ZNF683 zinc finger protein 683

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Yikan Sun and Eloy Yinwang contributed equally to this work.
==== Refs
References

1. Sun L Su Y Jiao A Wang X Zhang B T cells in health and disease Signal Transduct Target Ther 2023 8 235 10.1038/s41392-023-01471-y 37332039
Sun L, Su Y, Jiao A, Wang X, Zhang B. T cells in health and disease. Signal Transduct Target Ther. 2023;8:235.37332039 10.1038/s41392-023-01471-y
2. Bruni D Angell HK Galon J The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy Nat Rev Cancer 2020 20 662 80 10.1038/s41568-020-0285-7 32753728
Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20:662–80.32753728 10.1038/s41568-020-0285-7
3. Brummel K Eerkens AL de Bruyn M Nijman HW Tumour-infiltrating lymphocytes: from prognosis to treatment selection Br J Cancer 2023 128 451 8 10.1038/s41416-022-02119-4 36564565
Brummel K, Eerkens AL, de Bruyn M, Nijman HW. Tumour-infiltrating lymphocytes: from prognosis to treatment selection. Br J Cancer. 2023;128:451–8.36564565 10.1038/s41416-022-02119-4
4. Zheng L Qin S Si W Wang A Xing B Gao R Pan-cancer single-cell landscape of tumor-infiltrating T cells Science 2021 374 abe6474 10.1126/science.abe6474 34914499
Zheng L, Qin S, Si W, Wang A, Xing B, Gao R, et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science. 2021;374:abe6474.34914499 10.1126/science.abe6474
5. Rao A Barkley D França GS Yanai I Exploring tissue architecture using spatial transcriptomics Nature 2021 596 211 20 10.1038/s41586-021-03634-9 34381231
Rao A, Barkley D, França GS, Yanai I. Exploring tissue architecture using spatial transcriptomics. Nature. 2021;596:211–20.34381231 10.1038/s41586-021-03634-9
6. Schenkel JM Pauken KE Localization, tissue biology and T cell state — implications for cancer immunotherapy Nat Rev Immunol 2023 23 807 23 10.1038/s41577-023-00884-8 37253877
Schenkel JM, Pauken KE. Localization, tissue biology and T cell state — implications for cancer immunotherapy. Nat Rev Immunol. 2023;23:807–23.37253877 10.1038/s41577-023-00884-8
7. Domcke S Shendure J A reference cell tree will serve science better than a reference cell atlas Cell 2023 186 1103 14 10.1016/j.cell.2023.02.016 36931241
Domcke S, Shendure J. A reference cell tree will serve science better than a reference cell atlas. Cell. 2023;186:1103–14.36931241 10.1016/j.cell.2023.02.016
8. van den Broek T Borghans JAM van Wijk F The full spectrum of human naive T cells Nat Rev Immunol 2018 18 363 73 10.1038/s41577-018-0001-y 29520044
van den Broek T, Borghans JAM, van Wijk F. The full spectrum of human naive T cells. Nat Rev Immunol. 2018;18:363–73.29520044 10.1038/s41577-018-0001-y
9. Philip M Schietinger A CD8+ T cell differentiation and dysfunction in cancer Nat Rev Immunol 2022 22 209 23 10.1038/s41577-021-00574-3 34253904
Philip M, Schietinger A. CD8+ T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2022;22:209–23.34253904 10.1038/s41577-021-00574-3
10. Naulaerts S Datsi A Borras DM Antoranz Martinez A Messiaen J Vanmeerbeek I Multiomics and spatial mapping characterizes human CD8+ T cell states in cancer Sci Transl Med 2023 15 eadd1016 10.1126/scitranslmed.add1016 37043555
Naulaerts S, Datsi A, Borras DM, Antoranz Martinez A, Messiaen J, Vanmeerbeek I, et al. Multiomics and spatial mapping characterizes human CD8+ T cell states in cancer. Sci Transl Med. 2023;15:eadd1016.37043555 10.1126/scitranslmed.add1016
11. Van Der Byl W Nüssing S Peters TJ Ahn A Li H Ledergor G The CD8+ T cell tolerance checkpoint triggers a distinct differentiation state defined by protein translation defects Immunity 2024 57 1324 44 10.1016/j.immuni.2024.04.026 38776918
Van Der Byl W, Nüssing S, Peters TJ, Ahn A, Li H, Ledergor G, et al. The CD8+ T cell tolerance checkpoint triggers a distinct differentiation state defined by protein translation defects. Immunity. 2024;57:1324–44. e8.38776918 10.1016/j.immuni.2024.04.026
12. Chang JT Wherry EJ Goldrath AW Molecular regulation of effector and memory T cell differentiation Nat Immunol 2014 15 1104 15 10.1038/ni.3031 25396352
Chang JT, Wherry EJ, Goldrath AW. Molecular regulation of effector and memory T cell differentiation. Nat Immunol. 2014;15:1104–15.25396352 10.1038/ni.3031
13. Zhang N Hartig H Dzhagalov I Draper D He YW The role of apoptosis in the development and function of T lymphocytes Cell Res 2005 15 749 69 10.1038/sj.cr.7290345 16246265
Zhang N, Hartig H, Dzhagalov I, Draper D, He YW. The role of apoptosis in the development and function of T lymphocytes. Cell Res. 2005;15:749–69.16246265 10.1038/sj.cr.7290345
14. Huang Q Wu X Wang Z Chen X Wang L Lu Y The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes Cell 2022 185 4049 66 10.1016/j.cell.2022.09.020 36208623
Huang Q, Wu X, Wang Z, Chen X, Wang L, Lu Y, et al. The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. Cell. 2022;185:4049–66. e25.36208623 10.1016/j.cell.2022.09.020
15. Li Z, Tuong ZK, Dean I, Willis C, Gaspal F, Fiancette R et al. In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue. J Exp Med. 2022;219.
16. Gebhardt T, Park SL, Parish IA. Stem-like exhausted and memory CD8 + T cells in cancer. Nat Rev Cancer. 2023.
17. Andreatta M Corria-Osorio J Müller S Cubas R Coukos G Carmona SJ Interpretation of T cell states from single-cell transcriptomics data using reference atlases Nat Commun 2021 12 2965 10.1038/s41467-021-23324-4 34017005
Andreatta M, Corria-Osorio J, Müller S, Cubas R, Coukos G, Carmona SJ. Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nat Commun. 2021;12:2965.34017005 10.1038/s41467-021-23324-4
18. Oliveira G Stromhaug K Klaeger S Kula T Frederick DT Le PM Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma Nature 2021 596 119 25 10.1038/s41586-021-03704-y 34290406
Oliveira G, Stromhaug K, Klaeger S, Kula T, Frederick DT, Le PM, et al. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature. 2021;596:119–25.34290406 10.1038/s41586-021-03704-y
19. Guo X Zhang Y Zheng L Zheng C Song J Zhang Q Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing Nat Med 2018 24 978 85 10.1038/s41591-018-0045-3 29942094
Guo X, Zhang Y, Zheng L, Zheng C, Song J, Zhang Q, et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat Med. 2018;24:978–85.29942094 10.1038/s41591-018-0045-3
20. Sallusto F Lenig D Förster R Lipp M Lanzavecchia A Two subsets of memory T lymphocytes with distinct homing potentials and effector functions Nature 1999 401 708 12 10.1038/44385 10537110
Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708–12.10537110 10.1038/44385
21. Lin WW Nish SA Yen B Chen YH Adams WC Kratchmarov R CD8+ T lymphocyte Self-Renewal during Effector Cell determination Cell Rep 2016 17 1773 82 10.1016/j.celrep.2016.10.032 27829149
Lin WW, Nish SA, Yen B, Chen YH, Adams WC, Kratchmarov R, et al. CD8+ T lymphocyte Self-Renewal during Effector Cell determination. Cell Rep. 2016;17:1773–82.27829149 10.1016/j.celrep.2016.10.032
22. Pais Ferreira D Silva JG Wyss T Fuertes Marraco SA Scarpellino L Charmoy M Central memory CD8+ T cells derive from stem-like Tcf7hi effector cells in the absence of cytotoxic differentiation Immunity 2020 53 985 e100011 10.1016/j.immuni.2020.09.005 33128876
Pais Ferreira D, Silva JG, Wyss T, Fuertes Marraco SA, Scarpellino L, Charmoy M, et al. Central memory CD8+ T cells derive from stem-like Tcf7hi effector cells in the absence of cytotoxic differentiation. Immunity. 2020;53:985–e100011.33128876 10.1016/j.immuni.2020.09.005
23. Bresser K Kok L Swain AC King LA Jacobs L Weber TS Replicative history marks transcriptional and functional disparity in the CD8+ T cell memory pool Nat Immunol 2022 23 791 801 10.1038/s41590-022-01171-9 35393592
Bresser K, Kok L, Swain AC, King LA, Jacobs L, Weber TS, et al. Replicative history marks transcriptional and functional disparity in the CD8+ T cell memory pool. Nat Immunol. 2022;23:791–801.35393592 10.1038/s41590-022-01171-9
24. Graef P Buchholz VR Stemberger C Flossdorf M Henkel L Schiemann M Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8+ central memory T cells Immunity 2014 41 116 26 10.1016/j.immuni.2014.05.018 25035956
Graef P, Buchholz VR, Stemberger C, Flossdorf M, Henkel L, Schiemann M, et al. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8+ central memory T cells. Immunity. 2014;41:116–26.25035956 10.1016/j.immuni.2014.05.018
25. Sallusto F Geginat J Lanzavecchia A Central memory and effector memory T cell subsets: function, generation, and maintenance Annu Rev Immunol 2004 22 745 63 10.1146/annurev.immunol.22.012703.104702 15032595
Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745–63.15032595 10.1146/annurev.immunol.22.012703.104702
26. Gattinoni L Lugli E Ji Y Pos Z Paulos CM Quigley MF A human memory T cell subset with stem cell-like properties Nat Med 2011 17 1290 7 10.1038/nm.2446 21926977
Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17:1290–7.21926977 10.1038/nm.2446
27. Cieri N Camisa B Cocchiarella F Forcato M Oliveira G Provasi E IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors Blood 2013 121 573 84 10.1182/blood-2012-05-431718 23160470
Cieri N, Camisa B, Cocchiarella F, Forcato M, Oliveira G, Provasi E, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood. 2013;121:573–84.23160470 10.1182/blood-2012-05-431718
28. Roberto A Castagna L Zanon V Bramanti S Crocchiolo R McLaren JE Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation Blood 2015 125 2855 64 10.1182/blood-2014-11-608406 25742699
Roberto A, Castagna L, Zanon V, Bramanti S, Crocchiolo R, McLaren JE, et al. Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. Blood. 2015;125:2855–64.25742699 10.1182/blood-2014-11-608406
29. Gattinoni L Zhong XS Palmer DC Ji Y Hinrichs CS Yu Z Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells Nat Med 2009 15 808 13 10.1038/nm.1982 19525962
Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med. 2009;15:808–13.19525962 10.1038/nm.1982
30. Verma V Jafarzadeh N Boi S Kundu S Jiang Z Fan Y MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects Nat Immunol 2021 22 53 66 10.1038/s41590-020-00818-9 33230330
Verma V, Jafarzadeh N, Boi S, Kundu S, Jiang Z, Fan Y, et al. MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects. Nat Immunol. 2021;22:53–66.33230330 10.1038/s41590-020-00818-9
31. Galletti G De Simone G Mazza EMC Puccio S Mezzanotte C Bi TM Two subsets of stem-like CD8+ memory T cell progenitors with distinct fate commitments in humans Nat Immunol 2020 21 1552 62 10.1038/s41590-020-0791-5 33046887
Galletti G, De Simone G, Mazza EMC, Puccio S, Mezzanotte C, Bi TM, et al. Two subsets of stem-like CD8+ memory T cell progenitors with distinct fate commitments in humans. Nat Immunol. 2020;21:1552–62.33046887 10.1038/s41590-020-0791-5
32. Zheng C Zheng L Yoo J-K Guo H Zhang Y Guo X Landscape of infiltrating T cells in Liver Cancer revealed by single-cell sequencing Cell 2017 169 1342 e5616 10.1016/j.cell.2017.05.035 28622514
Zheng C, Zheng L, Yoo J-K, Guo H, Zhang Y, Guo X, et al. Landscape of infiltrating T cells in Liver Cancer revealed by single-cell sequencing. Cell. 2017;169:1342–e5616.28622514 10.1016/j.cell.2017.05.035
33. Zhang L Yu X Zheng L Zhang Y Li Y Fang Q Lineage tracking reveals dynamic relationships of T cells in colorectal cancer Nature 2018 564 268 72 10.1038/s41586-018-0694-x 30479382
Zhang L, Yu X, Zheng L, Zhang Y, Li Y, Fang Q, et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature. 2018;564:268–72.30479382 10.1038/s41586-018-0694-x
34. Sabatino M Hu J Sommariva M Gautam S Fellowes V Hocker JD Generation of clinical-grade CD19-specific CAR-modified CD8 + memory stem cells for the treatment of human B-cell malignancies Blood 2016 128 519 28 10.1182/blood-2015-11-683847 27226436
Sabatino M, Hu J, Sommariva M, Gautam S, Fellowes V, Hocker JD, et al. Generation of clinical-grade CD19-specific CAR-modified CD8 + memory stem cells for the treatment of human B-cell malignancies. Blood. 2016;128:519–28.27226436 10.1182/blood-2015-11-683847
35. Arcangeli S, Bove C, Mezzanotte C, Camisa B, Falcone L, Manfredi F et al. CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J Clin Invest. 2022;132.
36. Hurton LV Singh H Najjar AM Switzer KC Mi T Maiti S Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells Proc Natl Acad Sci U S A 2016 113 E7788 97 10.1073/pnas.1610544113 27849617
Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, Maiti S, et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci U S A. 2016;113:E7788–97.27849617 10.1073/pnas.1610544113
37. Meyran D Zhu JJ Butler J Tantalo D MacDonald S Nguyen TN TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models Sci Transl Med 2023 15 eabk1900 10.1126/scitranslmed.abk1900 37018415
Meyran D, Zhu JJ, Butler J, Tantalo D, MacDonald S, Nguyen TN, et al. TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models. Sci Transl Med. 2023;15:eabk1900.37018415 10.1126/scitranslmed.abk1900
38. Adachi K Kano Y Nagai T Okuyama N Sakoda Y Tamada K IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor Nat Biotechnol 2018 36 346 51 10.1038/nbt.4086 29505028
Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018;36:346–51.29505028 10.1038/nbt.4086
39. Masopust D Vezys V Marzo AL Lefrançois L Preferential localization of effector memory cells in nonlymphoid tissue Science 2001 291 2413 7 10.1126/science.1058867 11264538
Masopust D, Vezys V, Marzo AL, Lefrançois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science. 2001;291:2413–7.11264538 10.1126/science.1058867
40. Gebhardt T Wakim LM Eidsmo L Reading PC Heath WR Carbone FR Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus Nat Immunol 2009 10 524 30 10.1038/ni.1718 19305395
Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol. 2009;10:524–30.19305395 10.1038/ni.1718
41. Masopust D Choo D Vezys V Wherry EJ Duraiswamy J Akondy R Dynamic T cell migration program provides resident memory within intestinal epithelium J Exp Med 2010 207 553 64 10.1084/jem.20090858 20156972
Masopust D, Choo D, Vezys V, Wherry EJ, Duraiswamy J, Akondy R, et al. Dynamic T cell migration program provides resident memory within intestinal epithelium. J Exp Med. 2010;207:553–64.20156972 10.1084/jem.20090858
42. Yenyuwadee S Sanchez-Trincado Lopez JL Shah R Rosato PC Boussiotis VA The evolving role of tissue-resident memory T cells in infections and cancer Sci Adv 2022 8 eabo5871 10.1126/sciadv.abo5871 35977028
Yenyuwadee S, Sanchez-Trincado Lopez JL, Shah R, Rosato PC, Boussiotis VA. The evolving role of tissue-resident memory T cells in infections and cancer. Sci Adv. 2022;8:eabo5871.35977028 10.1126/sciadv.abo5871
43. Buggert M Price DA Mackay LK Betts MR Human circulating and tissue-resident memory CD8 + T cells Nat Immunol 2023 24 1076 86 10.1038/s41590-023-01538-6 37349380
Buggert M, Price DA, Mackay LK, Betts MR. Human circulating and tissue-resident memory CD8 + T cells. Nat Immunol. 2023;24:1076–86.37349380 10.1038/s41590-023-01538-6
44. Poon MML Caron DP Wang Z Wells SB Chen D Meng W Tissue adaptation and clonal segregation of human memory T cells in barrier sites Nat Immunol 2023 24 309 19 10.1038/s41590-022-01395-9 36658238
Poon MML, Caron DP, Wang Z, Wells SB, Chen D, Meng W, et al. Tissue adaptation and clonal segregation of human memory T cells in barrier sites. Nat Immunol. 2023;24:309–19.36658238 10.1038/s41590-022-01395-9
45. Szabo PA Levitin HM Miron M Snyder ME Senda T Yuan J Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease Nat Commun 2019 10 4706 10.1038/s41467-019-12464-3 31624246
Szabo PA, Levitin HM, Miron M, Snyder ME, Senda T, Yuan J, et al. Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease. Nat Commun. 2019;10:4706.31624246 10.1038/s41467-019-12464-3
46. Mackay LK Minnich M Kragten NA Liao Y Nota B Seillet C Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes Science 2016 352 459 63 10.1126/science.aad2035 27102484
Mackay LK, Minnich M, Kragten NA, Liao Y, Nota B, Seillet C, et al. Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes. Science. 2016;352:459–63.27102484 10.1126/science.aad2035
47. Milner JJ Toma C Yu B Zhang K Omilusik K Phan AT Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours Nature 2017 552 253 7 10.1038/nature24993 29211713
Milner JJ, Toma C, Yu B, Zhang K, Omilusik K, Phan AT, et al. Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours. Nature. 2017;552:253–7.29211713 10.1038/nature24993
48. Hombrink P Helbig C Backer RA Piet B Oja AE Stark R Programs for the persistence, vigilance and control of human CD8 + lung-resident memory T cells Nat Immunol 2016 17 1467 78 10.1038/ni.3589 27776108
Hombrink P, Helbig C, Backer RA, Piet B, Oja AE, Stark R, et al. Programs for the persistence, vigilance and control of human CD8 + lung-resident memory T cells. Nat Immunol. 2016;17:1467–78.27776108 10.1038/ni.3589
49. Skon CN Lee JY Anderson KG Masopust D Hogquist KA Jameson SC Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ T cells Nat Immunol 2013 14 1285 93 10.1038/ni.2745 24162775
Skon CN, Lee JY, Anderson KG, Masopust D, Hogquist KA, Jameson SC. Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ T cells. Nat Immunol. 2013;14:1285–93.24162775 10.1038/ni.2745
50. Liikanen I, Lauhan C, Quon S, Omilusik K, Phan AT, Bartrolí LB et al. Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells. J Clin Invest. 2021;131.
51. Corgnac S Malenica I Mezquita L Auclin E Voilin E Kacher J CD103+CD8+ TRM cells accumulate in tumors of Anti-PD-1-Responder Lung Cancer patients and are tumor-reactive lymphocytes enriched with Tc17 Cell Rep Med 2020 1 100127 10.1016/j.xcrm.2020.100127 33205076
Corgnac S, Malenica I, Mezquita L, Auclin E, Voilin E, Kacher J, et al. CD103+CD8+ TRM cells accumulate in tumors of Anti-PD-1-Responder Lung Cancer patients and are tumor-reactive lymphocytes enriched with Tc17. Cell Rep Med. 2020;1:100127.33205076 10.1016/j.xcrm.2020.100127
52. Crowl JT Heeg M Ferry A Milner JJ Omilusik KD Toma C Tissue-resident memory CD8+ T cells possess unique transcriptional, epigenetic and functional adaptations to different tissue environments Nat Immunol 2022 23 1121 31 10.1038/s41590-022-01229-8 35761084
Crowl JT, Heeg M, Ferry A, Milner JJ, Omilusik KD, Toma C, et al. Tissue-resident memory CD8+ T cells possess unique transcriptional, epigenetic and functional adaptations to different tissue environments. Nat Immunol. 2022;23:1121–31.35761084 10.1038/s41590-022-01229-8
53. Malik BT, Byrne KT, Vella JL, Zhang P, Shabaneh TB, Steinberg SM et al. Resident memory T cells in the skin mediate durable immunity to melanoma. Sci Immunol. 2017;2.
54. Park SL Buzzai A Rautela J Hor JL Hochheiser K Effern M Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin Nature 2019 565 366 71 10.1038/s41586-018-0812-9 30598548
Park SL, Buzzai A, Rautela J, Hor JL, Hochheiser K, Effern M, et al. Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin. Nature. 2019;565:366–71.30598548 10.1038/s41586-018-0812-9
55. Virassamy B Caramia F Savas P Sant S Wang J Christo SN Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer Cancer Cell 2023 41 585 e6018 10.1016/j.ccell.2023.01.004 36827978
Virassamy B, Caramia F, Savas P, Sant S, Wang J, Christo SN, et al. Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer. Cancer Cell. 2023;41:585–e6018.36827978 10.1016/j.ccell.2023.01.004
56. Caushi JX Zhang J Ji Z Vaghasia A Zhang B Hsiue EH Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers Nature 2021 596 126 32 10.1038/s41586-021-03752-4 34290408
Caushi JX, Zhang J, Ji Z, Vaghasia A, Zhang B, Hsiue EH, et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature. 2021;596:126–32.34290408 10.1038/s41586-021-03752-4
57. Christian LS Wang L Lim B Deng D Wu H Wang XF Li QJ Resident memory T cells in tumor-distant tissues fortify against metastasis formation Cell Rep 2021 35 109118 10.1016/j.celrep.2021.109118 33979626
Christian LS, Wang L, Lim B, Deng D, Wu H, Wang XF, Li QJ. Resident memory T cells in tumor-distant tissues fortify against metastasis formation. Cell Rep. 2021;35:109118.33979626 10.1016/j.celrep.2021.109118
58. Molodtsov AK, Khatwani N, Vella JL, Lewis KA, Zhao Y, Han J et al. Resident memory CD8+ T cells in regional lymph nodes mediate immunity to metastatic melanoma. Immunity. 2021;54:2117-32.e7.
59. Han J Zhao Y Shirai K Molodtsov A Kolling FW Fisher JL Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy Nat Cancer 2021 2 300 11 10.1038/s43018-021-00180-1 34179824
Han J, Zhao Y, Shirai K, Molodtsov A, Kolling FW, Fisher JL, et al. Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy. Nat Cancer. 2021;2:300–11.34179824 10.1038/s43018-021-00180-1
60. Weeden CE, Gayevskiy V, Marceaux C, Batey D, Tan T, Yokote K et al. Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. Cancer Cell. 2023;41:837 – 52.e6.
61. Corgnac S, Damei I, Gros G, Caidi A, Terry S, Chouaib S et al. Cancer stem-like cells evade CD8+CD103+ tumor-resident memory T (TRM) lymphocytes by initiating an epithelial-to-mesenchymal transition program in a human lung tumor model. J Immunother Cancer. 2022;10.
62. O’Donnell JS Teng MWL Smyth MJ Cancer immunoediting and resistance to T cell-based immunotherapy Nat Reviews Clin Oncol 2019 16 151 67 10.1038/s41571-018-0142-8
O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Reviews Clin Oncol. 2019;16:151–67.10.1038/s41571-018-0142-8
63. Savas P Virassamy B Ye C Salim A Mintoff CP Caramia F Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis Nat Med 2018 24 986 93 10.1038/s41591-018-0078-7 29942092
Savas P, Virassamy B, Ye C, Salim A, Mintoff CP, Caramia F, et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat Med. 2018;24:986–93.29942092 10.1038/s41591-018-0078-7
64. Webb JR Milne K Watson P Deleeuw RJ Nelson BH Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer Clin Cancer Res 2014 20 434 44 10.1158/1078-0432.CCR-13-1877 24190978
Webb JR, Milne K, Watson P, Deleeuw RJ, Nelson BH. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res. 2014;20:434–44.24190978 10.1158/1078-0432.CCR-13-1877
65. Djenidi F Adam J Goubar A Durgeau A Meurice G de Montpréville V CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients J Immunol 2015 194 3475 86 10.4049/jimmunol.1402711 25725111
Djenidi F, Adam J, Goubar A, Durgeau A, Meurice G, de Montpréville V, et al. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol. 2015;194:3475–86.25725111 10.4049/jimmunol.1402711
66. Jaiswal A Verma A Dannenfelser R Melssen M Tirosh I Izar B An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes Cancer Cell 2022 40 524 e445 10.1016/j.ccell.2022.04.005 35537413
Jaiswal A, Verma A, Dannenfelser R, Melssen M, Tirosh I, Izar B, et al. An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes. Cancer Cell. 2022;40:524–e445.35537413 10.1016/j.ccell.2022.04.005
67. Edwards J Wilmott JS Madore J Gide TN Quek C Tasker A CD103+ tumor-resident CD8+ T cells are Associated with Improved Survival in Immunotherapy-Naïve Melanoma patients and Expand significantly during Anti-PD-1 treatment Clin Cancer Res 2018 24 3036 45 10.1158/1078-0432.CCR-17-2257 29599411
Edwards J, Wilmott JS, Madore J, Gide TN, Quek C, Tasker A, et al. CD103+ tumor-resident CD8+ T cells are Associated with Improved Survival in Immunotherapy-Naïve Melanoma patients and Expand significantly during Anti-PD-1 treatment. Clin Cancer Res. 2018;24:3036–45.29599411 10.1158/1078-0432.CCR-17-2257
68. Duhen T Duhen R Montler R Moses J Moudgil T de Miranda NF Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors Nat Commun 2018 9 2724 10.1038/s41467-018-05072-0 30006565
Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda NF, et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. 2018;9:2724.30006565 10.1038/s41467-018-05072-0
69. Ganesan AP Clarke J Wood O Garrido-Martin EM Chee SJ Mellows T Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer Nat Immunol 2017 18 940 50 10.1038/ni.3775 28628092
Ganesan AP, Clarke J, Wood O, Garrido-Martin EM, Chee SJ, Mellows T, et al. Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nat Immunol. 2017;18:940–50.28628092 10.1038/ni.3775
70. Anadon CM, Yu X, Hänggi K, Biswas S, Chaurio RA, Martin A et al. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell. 2022;40:545 – 57.e13.
71. Barsch M Salié H Schlaak AE Zhang Z Hess M Mayer LS T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma J Hepatol 2022 77 397 409 10.1016/j.jhep.2022.02.032 35367533
Barsch M, Salié H, Schlaak AE, Zhang Z, Hess M, Mayer LS, et al. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. J Hepatol. 2022;77:397–409.35367533 10.1016/j.jhep.2022.02.032
72. Gueguen P, Metoikidou C, Dupic T, Lawand M, Goudot C, Baulande S et al. Contribution of resident and circulating precursors to tumor-infiltrating CD8+ T cell populations in lung cancer. Sci Immunol. 2021;6.
73. Krishna C, DiNatale RG, Kuo F, Srivastava RM, Vuong L, Chowell D et al. Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. Cancer Cell. 2021;39:662 – 77.e6.
74. Luoma AM, Suo S, Wang Y, Gunasti L, Porter CBM, Nabilsi N et al. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell. 2022;185:2918-35.e29.
75. Gavil NV Scott MC Weyu E Smith OC O’Flanagan SD Wijeyesinghe S Chronic antigen in solid tumors drives a distinct program of T cell residence Sci Immunol 2023 8 eadd5976 10.1126/sciimmunol.add5976 37267383
Gavil NV, Scott MC, Weyu E, Smith OC, O’Flanagan SD, Wijeyesinghe S, et al. Chronic antigen in solid tumors drives a distinct program of T cell residence. Sci Immunol. 2023;8:eadd5976.37267383 10.1126/sciimmunol.add5976
76. Siddiqui I Schaeuble K Chennupati V Fuertes Marraco SA Calderon-Copete S Pais Ferreira D Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like Properties promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy Immunity 2019 50 195 e21110 10.1016/j.immuni.2018.12.021 30635237
Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, et al. Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like Properties promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. Immunity. 2019;50:195–e21110.30635237 10.1016/j.immuni.2018.12.021
77. Wu J Madi A Mieg A Hotz-Wagenblatt A Weisshaar N Ma S T cell factor 1 suppresses CD103+ lung tissue-Resident memory T cell development Cell Rep 2020 31 107484 10.1016/j.celrep.2020.03.048 32268106
Wu J, Madi A, Mieg A, Hotz-Wagenblatt A, Weisshaar N, Ma S, et al. T cell factor 1 suppresses CD103+ lung tissue-Resident memory T cell development. Cell Rep. 2020;31:107484.32268106 10.1016/j.celrep.2020.03.048
78. Zehn D Thimme R Lugli E de Almeida GP Oxenius A Stem-like’ precursors are the fount to sustain persistent CD8+ T cell responses Nat Immunol 2022 23 836 47 10.1038/s41590-022-01219-w 35624209
Zehn D, Thimme R, Lugli E, de Almeida GP, Oxenius A. Stem-like’ precursors are the fount to sustain persistent CD8+ T cell responses. Nat Immunol. 2022;23:836–47.35624209 10.1038/s41590-022-01219-w
79. Lan X Mi T Alli S Guy C Djekidel MN Liu X Antitumor progenitor exhausted CD8+ T cells are sustained by TCR engagement Nat Immunol 2024 25 1046 58 10.1038/s41590-024-01843-8 38816618
Lan X, Mi T, Alli S, Guy C, Djekidel MN, Liu X, et al. Antitumor progenitor exhausted CD8+ T cells are sustained by TCR engagement. Nat Immunol. 2024;25:1046–58.38816618 10.1038/s41590-024-01843-8
80. Shakiba M, Zumbo P, Espinosa-Carrasco G, Menocal L, Dündar F, Carson SE et al. TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. J Exp Med. 2022;219.
81. Daniel B Yost KE Hsiung S Sandor K Xia Y Qi Y Divergent clonal differentiation trajectories of T cell exhaustion Nat Immunol 2022 23 1614 27 10.1038/s41590-022-01337-5 36289450
Daniel B, Yost KE, Hsiung S, Sandor K, Xia Y, Qi Y, et al. Divergent clonal differentiation trajectories of T cell exhaustion. Nat Immunol. 2022;23:1614–27.36289450 10.1038/s41590-022-01337-5
82. + progenitor CD8 T cell phenotypes in tumors. Cell. 2021;184:4996–5014.e26.
83. Schietinger A Philip M Krisnawan VE Chiu EY Delrow JJ Basom RS Tumor-specific T cell dysfunction is a dynamic Antigen-Driven differentiation program initiated early during Tumorigenesis Immunity 2016 45 389 401 10.1016/j.immuni.2016.07.011 27521269
Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, et al. Tumor-specific T cell dysfunction is a dynamic Antigen-Driven differentiation program initiated early during Tumorigenesis. Immunity. 2016;45:389–401.27521269 10.1016/j.immuni.2016.07.011
84. Pritykin Y van der Veeken J Pine AR Zhong Y Sahin M Mazutis L A unified atlas of CD8 T cell dysfunctional states in cancer and infection Mol Cell 2021 81 2477 e9310 10.1016/j.molcel.2021.03.045 33891860
Pritykin Y, van der Veeken J, Pine AR, Zhong Y, Sahin M, Mazutis L, et al. A unified atlas of CD8 T cell dysfunctional states in cancer and infection. Mol Cell. 2021;81:2477–e9310.33891860 10.1016/j.molcel.2021.03.045
85. Angelosanto JM Wherry EJ Transcription factor regulation of CD8+ T-cell memory and exhaustion Immunol Rev 2010 236 167 75 10.1111/j.1600-065X.2010.00927.x 20636816
Angelosanto JM, Wherry EJ. Transcription factor regulation of CD8+ T-cell memory and exhaustion. Immunol Rev. 2010;236:167–75.20636816 10.1111/j.1600-065X.2010.00927.x
86. Rudloff MW Zumbo P Favret NR Roetman JJ Detrés Román CR Erwin MM Hallmarks of CD8+ T cell dysfunction are established within hours of tumor antigen encounter before cell division Nat Immunol 2023 24 1527 39 10.1038/s41590-023-01578-y 37537361
Rudloff MW, Zumbo P, Favret NR, Roetman JJ, Detrés Román CR, Erwin MM, et al. Hallmarks of CD8+ T cell dysfunction are established within hours of tumor antigen encounter before cell division. Nat Immunol. 2023;24:1527–39.37537361 10.1038/s41590-023-01578-y
87. Scott AC Dündar F Zumbo P Chandran SS Klebanoff CA Shakiba M TOX is a critical regulator of tumour-specific T cell differentiation Nature 2019 571 270 4 10.1038/s41586-019-1324-y 31207604
Scott AC, Dündar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019;571:270–4.31207604 10.1038/s41586-019-1324-y
88. Philip M Fairchild L Sun L Horste EL Camara S Shakiba M Chromatin states define tumour-specific T cell dysfunction and reprogramming Nature 2017 545 452 6 10.1038/nature22367 28514453
Philip M, Fairchild L, Sun L, Horste EL, Camara S, Shakiba M, et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. 2017;545:452–6.28514453 10.1038/nature22367
89. Li H, van der Leun AM, Yofe I, Lubling Y, Gelbard-Solodkin D, van Akkooi ACJ et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell. 2019;176:775 – 89.e18.
90. Sade-Feldman M Yizhak K Bjorgaard SL Ray JP de Boer CG Jenkins RW Defining T Cell States Associated with response to Checkpoint Immunotherapy in Melanoma Cell 2018 175 998 e101320 10.1016/j.cell.2018.10.038 30388456
Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, et al. Defining T Cell States Associated with response to Checkpoint Immunotherapy in Melanoma. Cell. 2018;175:998–e101320.30388456 10.1016/j.cell.2018.10.038
91. Utzschneider DT Legat A Fuertes Marraco SA Carrié L Luescher I Speiser DE Zehn D T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion Nat Immunol 2013 14 603 10 10.1038/ni.2606 23644506
Utzschneider DT, Legat A, Fuertes Marraco SA, Carrié L, Luescher I, Speiser DE, Zehn D. T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol. 2013;14:603–10.23644506 10.1038/ni.2606
92. Abdel-Hakeem MS Manne S Beltra J-C Stelekati E Chen Z Nzingha K Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation Nat Immunol 2021 22 1008 19 10.1038/s41590-021-00975-5 34312545
Abdel-Hakeem MS, Manne S, Beltra J-C, Stelekati E, Chen Z, Nzingha K, et al. Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation. Nat Immunol. 2021;22:1008–19.34312545 10.1038/s41590-021-00975-5
93. Martinez GJ Pereira RM Äijö T Kim EY Marangoni F Pipkin ME The transcription factor NFAT promotes exhaustion of activated CD8⁺ T cells Immunity 2015 42 265 78 10.1016/j.immuni.2015.01.006 25680272
Martinez GJ, Pereira RM, Äijö T, Kim EY, Marangoni F, Pipkin ME, et al. The transcription factor NFAT promotes exhaustion of activated CD8⁺ T cells. Immunity. 2015;42:265–78.25680272 10.1016/j.immuni.2015.01.006
94. Dash B Hogan PG The road not taken en route to T cell exhaustion Nat Immunol 2023 24 1402 4 10.1038/s41590-023-01596-w 37580606
Dash B, Hogan PG. The road not taken en route to T cell exhaustion. Nat Immunol. 2023;24:1402–4.37580606 10.1038/s41590-023-01596-w
95. Mognol GP Spreafico R Wong V Scott-Browne JP Togher S Hoffmann A Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells Proc Natl Acad Sci U S A 2017 114 E2776 85 10.1073/pnas.1620498114 28283662
Mognol GP, Spreafico R, Wong V, Scott-Browne JP, Togher S, Hoffmann A, et al. Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells. Proc Natl Acad Sci U S A. 2017;114:E2776–85.28283662 10.1073/pnas.1620498114
96. Tillé L Cropp D Charmoy M Reichenbach P Andreatta M Wyss T Activation of the transcription factor NFAT5 in the tumor microenvironment enforces CD8+ T cell exhaustion Nat Immunol 2023 24 1645 53 10.1038/s41590-023-01614-x 37709986
Tillé L, Cropp D, Charmoy M, Reichenbach P, Andreatta M, Wyss T, et al. Activation of the transcription factor NFAT5 in the tumor microenvironment enforces CD8+ T cell exhaustion. Nat Immunol. 2023;24:1645–53.37709986 10.1038/s41590-023-01614-x
97. Chen J López-Moyado IF Seo H Lio C-WJ Hempleman LJ Sekiya T NR4A transcription factors limit CAR T cell function in solid tumours Nature 2019 567 530 4 10.1038/s41586-019-0985-x 30814732
Chen J, López-Moyado IF, Seo H, Lio C-WJ, Hempleman LJ, Sekiya T, et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019;567:530–4.30814732 10.1038/s41586-019-0985-x
98. Lynn RC Weber EW Sotillo E Gennert D Xu P Good Z c-Jun overexpression in CAR T cells induces exhaustion resistance Nature 2019 576 293 300 10.1038/s41586-019-1805-z 31802004
Lynn RC, Weber EW, Sotillo E, Gennert D, Xu P, Good Z, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature. 2019;576:293–300.31802004 10.1038/s41586-019-1805-z
99. Seo H González-Avalos E Zhang W Ramchandani P Yang C Lio CJ BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells Nat Immunol 2021 22 983 95 10.1038/s41590-021-00964-8 34282330
Seo H, González-Avalos E, Zhang W, Ramchandani P, Yang C, Lio CJ, et al. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat Immunol. 2021;22:983–95.34282330 10.1038/s41590-021-00964-8
100. Khan O Giles JR McDonald S Manne S Ngiow SF Patel KP TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion Nature 2019 571 211 8 10.1038/s41586-019-1325-x 31207603
Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature. 2019;571:211–8.31207603 10.1038/s41586-019-1325-x
101. Sekine T Perez-Potti A Nguyen S Gorin J-B Wu VH Gostick E TOX is expressed by exhausted and polyfunctional human effector memory CD8+ T cells Sci Immunol 2020 5 eaba7918 10.1126/sciimmunol.aba7918 32620560
Sekine T, Perez-Potti A, Nguyen S, Gorin J-B, Wu VH, Gostick E, et al. TOX is expressed by exhausted and polyfunctional human effector memory CD8+ T cells. Sci Immunol. 2020;5:eaba7918.32620560 10.1126/sciimmunol.aba7918
102. Alfei F Kanev K Hofmann M Wu M Ghoneim HE Roelli P TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection Nature 2019 571 265 9 10.1038/s41586-019-1326-9 31207605
Alfei F, Kanev K, Hofmann M, Wu M, Ghoneim HE, Roelli P, et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature. 2019;571:265–9.31207605 10.1038/s41586-019-1326-9
103. Beltra JC, Manne S, Abdel-Hakeem MS, Kurachi M, Giles JR, Chen Z et al. Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic Landscape Control mechanisms. Immunity. 2020;52:825 – 41.e8.
104. Pauken KE Sammons MA Odorizzi PM Manne S Godec J Khan O Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade Science 2016 354 1160 5 10.1126/science.aaf2807 27789795
Pauken KE, Sammons MA, Odorizzi PM, Manne S, Godec J, Khan O, et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science. 2016;354:1160–5.27789795 10.1126/science.aaf2807
105. Im SJ Hashimoto M Gerner MY Lee J Kissick HT Burger MC Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy Nature 2016 537 417 21 10.1038/nature19330 27501248
Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016;537:417–21.27501248 10.1038/nature19330
106. Jansen CS Prokhnevska N Master VA Sanda MG Carlisle JW Bilen MA An intra-tumoral niche maintains and differentiates stem-like CD8 T cells Nature 2019 576 465 70 10.1038/s41586-019-1836-5 31827286
Jansen CS, Prokhnevska N, Master VA, Sanda MG, Carlisle JW, Bilen MA, et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature. 2019;576:465–70.31827286 10.1038/s41586-019-1836-5
107. Liu B Hu X Feng K Gao R Xue Z Zhang S Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer Nat Cancer 2022 3 108 21 10.1038/s43018-021-00292-8 35121991
Liu B, Hu X, Feng K, Gao R, Xue Z, Zhang S, et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nat Cancer. 2022;3:108–21.35121991 10.1038/s43018-021-00292-8
108. Kurtulus S, Madi A, Escobar G, Klapholz M, Nyman J, Christian E et al. Checkpoint blockade immunotherapy induces dynamic changes in PD-1-CD8+ tumor-infiltrating T cells. Immunity. 2019;50:181 – 94.e6.
109. Miller BC Sen DR Al Abosy R Bi K Virkud YV LaFleur MW Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade Nat Immunol 2019 20 326 36 10.1038/s41590-019-0312-6 30778252
Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20:326–36.30778252 10.1038/s41590-019-0312-6
110. Brummelman J Mazza EMC Alvisi G Colombo FS Grilli A Mikulak J High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors J Exp Med 2018 215 2520 35 10.1084/jem.20180684 30154266
Brummelman J, Mazza EMC, Alvisi G, Colombo FS, Grilli A, Mikulak J, et al. High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors. J Exp Med. 2018;215:2520–35.30154266 10.1084/jem.20180684
111. Leong YA Chen Y Ong HS Wu D Man K Deleage C CXCR5+ follicular cytotoxic T cells control viral infection in B cell follicles Nat Immunol 2016 17 1187 96 10.1038/ni.3543 27487330
Leong YA, Chen Y, Ong HS, Wu D, Man K, Deleage C, et al. CXCR5+ follicular cytotoxic T cells control viral infection in B cell follicles. Nat Immunol. 2016;17:1187–96.27487330 10.1038/ni.3543
112. He R Hou S Liu C Zhang A Bai Q Han M Follicular CXCR5- expressing CD8+ T cells curtail chronic viral infection Nature 2016 537 412 28 10.1038/nature19317 27501245
He R, Hou S, Liu C, Zhang A, Bai Q, Han M, et al. Follicular CXCR5- expressing CD8+ T cells curtail chronic viral infection. Nature. 2016;537:412–28.27501245 10.1038/nature19317
113. Yost KE Satpathy AT Wells DK Qi Y Wang C Kageyama R Clonal replacement of tumor-specific T cells following PD-1 blockade Nat Med 2019 25 1251 9 10.1038/s41591-019-0522-3 31359002
Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019;25:1251–9.31359002 10.1038/s41591-019-0522-3
114. Wu T, Ji Y, Moseman EA, Xu HC, Manglani M, Kirby M et al. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Sci Immunol. 2016;1.
115. Staron MM Gray SM Marshall HD Parish IA Chen JH Perry CJ The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8+ T cells during chronic infection Immunity 2014 41 802 14 10.1016/j.immuni.2014.10.013 25464856
Staron MM, Gray SM, Marshall HD, Parish IA, Chen JH, Perry CJ, et al. The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8+ T cells during chronic infection. Immunity. 2014;41:802–14.25464856 10.1016/j.immuni.2014.10.013
116. Utzschneider DT Delpoux A Wieland D Huang X Lai CY Hofmann M Active maintenance of T cell memory in Acute and chronic viral infection depends on continuous expression of FOXO1 Cell Rep 2018 22 3454 67 10.1016/j.celrep.2018.03.020 29590615
Utzschneider DT, Delpoux A, Wieland D, Huang X, Lai CY, Hofmann M, et al. Active maintenance of T cell memory in Acute and chronic viral infection depends on continuous expression of FOXO1. Cell Rep. 2018;22:3454–67.29590615 10.1016/j.celrep.2018.03.020
117. Tsui C Kretschmer L Rapelius S Gabriel SS Chisanga D Knöpper K MYB orchestrates T cell exhaustion and response to checkpoint inhibition Nature 2022 609 354 60 10.1038/s41586-022-05105-1 35978192
Tsui C, Kretschmer L, Rapelius S, Gabriel SS, Chisanga D, Knöpper K, et al. MYB orchestrates T cell exhaustion and response to checkpoint inhibition. Nature. 2022;609:354–60.35978192 10.1038/s41586-022-05105-1
118. Yao C Lou G Sun HW Zhu Z Sun Y Chen Z BACH2 enforces the transcriptional and epigenetic programs of stem-like CD8+ T cells Nat Immunol 2021 22 370 80 10.1038/s41590-021-00868-7 33574619
Yao C, Lou G, Sun HW, Zhu Z, Sun Y, Chen Z, et al. BACH2 enforces the transcriptional and epigenetic programs of stem-like CD8+ T cells. Nat Immunol. 2021;22:370–80.33574619 10.1038/s41590-021-00868-7
119. Neubert EN DeRogatis JM Lewis SA Viramontes KM Ortega P Henriquez ML HMGB2 regulates the differentiation and stemness of exhausted CD8+ T cells during chronic viral infection and cancer Nat Commun 2023 14 5631 10.1038/s41467-023-41352-0 37704621
Neubert EN, DeRogatis JM, Lewis SA, Viramontes KM, Ortega P, Henriquez ML, et al. HMGB2 regulates the differentiation and stemness of exhausted CD8+ T cells during chronic viral infection and cancer. Nat Commun. 2023;14:5631.37704621 10.1038/s41467-023-41352-0
120. Zhao X Shan Q Xue H-H TCF1 in T cell immunity: a broadened frontier Nat Rev Immunol 2022 22 147 57 10.1038/s41577-021-00563-6 34127847
Zhao X, Shan Q, Xue H-H. TCF1 in T cell immunity: a broadened frontier. Nat Rev Immunol. 2022;22:147–57.34127847 10.1038/s41577-021-00563-6
121. Escobar G, Mangani D, Anderson AC. T cell factor 1: a master regulator of the T cell response in disease. Sci Immunol. 2020;5.
122. Shan Q Hu SS Zhu S Chen X Badovinac VP Peng W Tcf1 preprograms the mobilization of glycolysis in central memory CD8 + T cells during recall responses Nat Immunol 2022 23 386 98 10.1038/s41590-022-01131-3 35190717
Shan Q, Hu SS, Zhu S, Chen X, Badovinac VP, Peng W, et al. Tcf1 preprograms the mobilization of glycolysis in central memory CD8 + T cells during recall responses. Nat Immunol. 2022;23:386–98.35190717 10.1038/s41590-022-01131-3
123. Shan Q Hu S Chen X Danahy DB Badovinac VP Zang C Xue HH Ectopic Tcf1 expression instills a stem-like program in exhausted CD8+ T cells to enhance viral and tumor immunity Cell Mol Immunol 2021 18 1262 77 10.1038/s41423-020-0436-5 32341523
Shan Q, Hu S, Chen X, Danahy DB, Badovinac VP, Zang C, Xue HH. Ectopic Tcf1 expression instills a stem-like program in exhausted CD8+ T cells to enhance viral and tumor immunity. Cell Mol Immunol. 2021;18:1262–77.32341523 10.1038/s41423-020-0436-5
124. Escobar G, Tooley K, Oliveras JP, Huang L, Cheng H, Bookstaver ML et al. Tumor immunogenicity dictates reliance on TCF1 in CD8+ T cells for response to immunotherapy. Cancer Cell. 2023;41:1662-79.e7.
125. Chen Z, Ji Z, Ngiow SF, Manne S, Cai Z, Huang AC et al. TCF-1-Centered Transcriptional Network Drives an effector versus exhausted CD8 T cell-fate decision. Immunity. 2019;51:840 – 55.e5.
126. Krishna S Lowery FJ Copeland AR Bahadiroglu E Mukherjee R Jia L Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer Science 2020 370 1328 34 10.1126/science.abb9847 33303615
Krishna S, Lowery FJ, Copeland AR, Bahadiroglu E, Mukherjee R, Jia L, et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science. 2020;370:1328–34.33303615 10.1126/science.abb9847
127. Eberhardt CS Kissick HT Patel MR Cardenas MA Prokhnevska N Obeng RC Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer Nature 2021 597 279 84 10.1038/s41586-021-03862-z 34471285
Eberhardt CS, Kissick HT, Patel MR, Cardenas MA, Prokhnevska N, Obeng RC, et al. Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer. Nature. 2021;597:279–84.34471285 10.1038/s41586-021-03862-z
128. Nagate Y Ezoe S Fujita J Okuzaki D Motooka D Ishibashi T Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function Leukemia 2021 35 107 18 10.1038/s41375-020-0788-y 32203145
Nagate Y, Ezoe S, Fujita J, Okuzaki D, Motooka D, Ishibashi T, et al. Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function. Leukemia. 2021;35:107–18.32203145 10.1038/s41375-020-0788-y
129. Canale FP Ramello MC Núñez N Araujo Furlan CL Bossio SN Gorosito Serrán M CD39 expression defines cell exhaustion in Tumor-infiltrating CD8+ T cells Cancer Res 2018 78 115 28 10.1158/0008-5472.CAN-16-2684 29066514
Canale FP, Ramello MC, Núñez N, Araujo Furlan CL, Bossio SN, Gorosito Serrán M, et al. CD39 expression defines cell exhaustion in Tumor-infiltrating CD8+ T cells. Cancer Res. 2018;78:115–28.29066514 10.1158/0008-5472.CAN-16-2684
130. Hu G Cheng P Pan J Wang S Ding Q Jiang Z An IL6–Adenosine positive Feedback Loop between CD73+ γδTregs and CAFs promotes Tumor Progression in human breast Cancer Cancer Immunol Res 2020 8 1273 86 10.1158/2326-6066.CIR-19-0923 32847938
Hu G, Cheng P, Pan J, Wang S, Ding Q, Jiang Z, et al. An IL6–Adenosine positive Feedback Loop between CD73+ γδTregs and CAFs promotes Tumor Progression in human breast Cancer. Cancer Immunol Res. 2020;8:1273–86.32847938 10.1158/2326-6066.CIR-19-0923
131. Vignali PDA DePeaux K Watson MJ Ye C Ford BR Lontos K Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity Nat Immunol 2023 24 267 79 10.1038/s41590-022-01379-9 36543958
Vignali PDA, DePeaux K, Watson MJ, Ye C, Ford BR, Lontos K, et al. Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity. Nat Immunol. 2023;24:267–79.36543958 10.1038/s41590-022-01379-9
132. Perrot I, Michaud HA, Giraudon-Paoli M, Augier S, Docquier A, Gros L et al. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. Cell Rep. 2019;27:2411-25.e9.
133. Carlini V, Noonan DM, Abdalalem E, Goletti D, Sansone C, Calabrone L, Albini A. The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. Front Immunol. 2023;14.
134. Guo Y Xie Y-Q Gao M Zhao Y Franco F Wenes M Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity Nat Immunol 2021 22 746 56 10.1038/s41590-021-00940-2 34031618
Guo Y, Xie Y-Q, Gao M, Zhao Y, Franco F, Wenes M, et al. Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity. Nat Immunol. 2021;22:746–56.34031618 10.1038/s41590-021-00940-2
135. Qiao J Liu Z Dong C Luan Y Zhang A Moore C Targeting tumors with IL-10 prevents dendritic cell-mediated CD8+ T cell apoptosis Cancer Cell 2019 35 901 e154 10.1016/j.ccell.2019.05.005 31185213
Qiao J, Liu Z, Dong C, Luan Y, Zhang A, Moore C, et al. Targeting tumors with IL-10 prevents dendritic cell-mediated CD8+ T cell apoptosis. Cancer Cell. 2019;35:901–e154.31185213 10.1016/j.ccell.2019.05.005
136. Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP et al. PEGylated IL-10 (Pegilodecakin) induces systemic Immune activation, CD8+ T cell invigoration and polyclonal T cell expansion in Cancer patients. Cancer Cell. 2018;34:775 – 91.e3.
137. Naing A Wong DJ Infante JR Korn WM Aljumaily R Papadopoulos KP Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial Lancet Oncol 2019 20 1544 55 10.1016/S1470-2045(19)30514-5 31563517
Naing A, Wong DJ, Infante JR, Korn WM, Aljumaily R, Papadopoulos KP, et al. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019;20:1544–55.31563517 10.1016/S1470-2045(19)30514-5
138. Spigel D Jotte R Nemunaitis J Shum M Schneider J Goldschmidt J Randomized phase 2 studies of checkpoint inhibitors alone or in Combination with Pegilodecakin in patients with metastatic NSCLC (CYPRESS 1 and CYPRESS 2) J Thorac Oncol 2021 16 327 33 10.1016/j.jtho.2020.10.001 33166722
Spigel D, Jotte R, Nemunaitis J, Shum M, Schneider J, Goldschmidt J, et al. Randomized phase 2 studies of checkpoint inhibitors alone or in Combination with Pegilodecakin in patients with metastatic NSCLC (CYPRESS 1 and CYPRESS 2). J Thorac Oncol. 2021;16:327–33.33166722 10.1016/j.jtho.2020.10.001
139. Zander R, Schauder D, Xin G, Nguyen C, Wu X, Zajac A, Cui W. CD4+ T Cell Help Is Required for the Formation of a Cytolytic CD8+ T Cell Subset that Protects against Chronic Infection and Cancer. Immunity. 2019;51:1028-42.e4.
140. Hudson WH, Gensheimer J, Hashimoto M, Wieland A, Valanparambil RM, Li P et al. Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection. Immunity. 2019;51:1043-58.e4.
141. Rahim MK Okholm TLH Jones KB McCarthy EE Liu CC Yee JL Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes Cell 2023 186 1127 e4318 10.1016/j.cell.2023.02.021 36931243
Rahim MK, Okholm TLH, Jones KB, McCarthy EE, Liu CC, Yee JL, et al. Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell. 2023;186:1127–e4318.36931243 10.1016/j.cell.2023.02.021
142. Zhou P Shi H Huang H Sun X Yuan S Chapman NM Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer Nature 2023 624 154 63 10.1038/s41586-023-06733-x 37968405
Zhou P, Shi H, Huang H, Sun X, Yuan S, Chapman NM, et al. Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer. Nature. 2023;624:154–63.37968405 10.1038/s41586-023-06733-x
143. Magen A Hamon P Fiaschi N Soong BY Park MD Mattiuz R Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma Nat Med 2023 29 1389 99 10.1038/s41591-023-02345-0 37322116
Magen A, Hamon P, Fiaschi N, Soong BY, Park MD, Mattiuz R, et al. Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat Med. 2023;29:1389–99.37322116 10.1038/s41591-023-02345-0
144. Giles JR Ngiow SF Manne S Baxter AE Khan O Wang P Shared and distinct biological circuits in effector, memory and exhausted CD8+ T cells revealed by temporal single-cell transcriptomics and epigenetics Nat Immunol 2022 23 1600 13 10.1038/s41590-022-01338-4 36271148
Giles JR, Ngiow SF, Manne S, Baxter AE, Khan O, Wang P, et al. Shared and distinct biological circuits in effector, memory and exhausted CD8+ T cells revealed by temporal single-cell transcriptomics and epigenetics. Nat Immunol. 2022;23:1600–13.36271148 10.1038/s41590-022-01338-4
145. Wilson TL Kim H Chou CH Langfitt D Mettelman RC Minervina AA Common trajectories of highly effective CD19-Specific CAR T cells identified by endogenous T-cell receptor lineages Cancer Discov 2022 12 2098 119 10.1158/2159-8290.CD-21-1508 35792801
Wilson TL, Kim H, Chou CH, Langfitt D, Mettelman RC, Minervina AA, et al. Common trajectories of highly effective CD19-Specific CAR T cells identified by endogenous T-cell receptor lineages. Cancer Discov. 2022;12:2098–119.35792801 10.1158/2159-8290.CD-21-1508
146. Kasmani MY, Zander R, Chung HK, Chen Y, Khatun A, Damo M et al. Clonal lineage tracing reveals mechanisms skewing CD8 + T cell fate decisions in chronic infection. J Exp Med. 2023;220.
147. Chen Y Xu Z Sun H Ouyang X Han Y Yu H Regulation of CD8+ T memory and exhaustion by the mTOR signals Cell Mol Immunol 2023 20 1023 39 10.1038/s41423-023-01064-3 37582972
Chen Y, Xu Z, Sun H, Ouyang X, Han Y, Yu H, et al. Regulation of CD8+ T memory and exhaustion by the mTOR signals. Cell Mol Immunol. 2023;20:1023–39.37582972 10.1038/s41423-023-01064-3
148. Chen Y Zander RA Wu X Schauder DM Kasmani MY Shen J BATF regulates progenitor to cytolytic effector CD8+ T cell transition during chronic viral infection Nat Immunol 2021 22 996 1007 10.1038/s41590-021-00965-7 34282329
Chen Y, Zander RA, Wu X, Schauder DM, Kasmani MY, Shen J, et al. BATF regulates progenitor to cytolytic effector CD8+ T cell transition during chronic viral infection. Nat Immunol. 2021;22:996–1007.34282329 10.1038/s41590-021-00965-7
149. Zhu Z Lou G Teng X-L Wang H Luo Y Shi W FOXP1 and KLF2 reciprocally regulate checkpoints of stem-like to effector transition in CAR T cells Nat Immunol 2024 25 117 28 10.1038/s41590-023-01685-w 38012417
Zhu Z, Lou G, Teng X-L, Wang H, Luo Y, Shi W, et al. FOXP1 and KLF2 reciprocally regulate checkpoints of stem-like to effector transition in CAR T cells. Nat Immunol. 2024;25:117–28.38012417 10.1038/s41590-023-01685-w
150. Beltra J-C, Abdel-Hakeem MS, Manne S, Zhang Z, Huang H, Kurachi M et al. Stat5 opposes the transcription factor Tox and rewires exhausted CD8+ T cells toward durable effector-like states during chronic antigen exposure. Immunity. 2023;56:2699 – 718.e11.
151. Zander R Cui W Exhausted CD8+ T cells face a developmental fork in the road Trends Immunol 2023 44 276 86 10.1016/j.it.2023.02.006 36907685
Zander R, Cui W. Exhausted CD8+ T cells face a developmental fork in the road. Trends Immunol. 2023;44:276–86.36907685 10.1016/j.it.2023.02.006
152. Parry EM, Lemvigh CK, Deng S, Dangle N, Ruthen N, Knisbacher BA et al. ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. Cancer Cell. 2023;41:1803-16.e8.
153. Galon J Costes A Sanchez-Cabo F Kirilovsky A Mlecnik B Lagorce-Pagès C Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 2006 313 1960 4 10.1126/science.1129139 17008531
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4.17008531 10.1126/science.1129139
154. Pagès F Mlecnik B Marliot F Bindea G Ou FS Bifulco C International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study Lancet 2018 391 2128 39 10.1016/S0140-6736(18)30789-X 29754777
Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391:2128–39.29754777 10.1016/S0140-6736(18)30789-X
155. Galon J Bruni D Approaches to treat immune hot, altered and cold tumours with combination immunotherapies Nat Rev Drug Discovery 2019 18 197 218 10.1038/s41573-018-0007-y 30610226
Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discovery. 2019;18:197–218.30610226 10.1038/s41573-018-0007-y
156. Angell HK Bruni D Barrett JC Herbst R Galon J The immunoscore: Colon Cancer and Beyond Clin Cancer Res 2020 26 332 9 10.1158/1078-0432.CCR-18-1851 31413009
Angell HK, Bruni D, Barrett JC, Herbst R, Galon J. The immunoscore: Colon Cancer and Beyond. Clin Cancer Res. 2020;26:332–9.31413009 10.1158/1078-0432.CCR-18-1851
157. Chen Daniel S Mellman I Oncology meets immunology: the Cancer-Immunity cycle Immunity 2013 39 1 10 10.1016/j.immuni.2013.07.012 23890059
Chen Daniel S, Mellman I. Oncology meets immunology: the Cancer-Immunity cycle. Immunity. 2013;39:1–10.23890059 10.1016/j.immuni.2013.07.012
158. du Bois H Heim TA Lund AW Tumor-draining lymph nodes: at the crossroads of metastasis and immunity Sci Immunol 2021 6 eabg3551 10.1126/sciimmunol.abg3551 34516744
du Bois H, Heim TA, Lund AW. Tumor-draining lymph nodes: at the crossroads of metastasis and immunity. Sci Immunol. 2021;6:eabg3551.34516744 10.1126/sciimmunol.abg3551
159. Inamori K, Togashi Y, Fukuoka S, Akagi K, Ogasawara K, Irie T et al. Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer. JCI Insight. 2021;6.
160. Harter P Sehouli J Lorusso D Reuss A Vergote I Marth C A Randomized Trial of Lymphadenectomy in patients with Advanced Ovarian neoplasms N Engl J Med 2019 380 822 32 10.1056/NEJMoa1808424 30811909
Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. A Randomized Trial of Lymphadenectomy in patients with Advanced Ovarian neoplasms. N Engl J Med. 2019;380:822–32.30811909 10.1056/NEJMoa1808424
161. Fear VS Forbes CA Neeve SA Fisher SA Chee J Waithman J Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used Cancer Immunol Immunother 2021 70 3249 58 10.1007/s00262-021-02934-3 33835222
Fear VS, Forbes CA, Neeve SA, Fisher SA, Chee J, Waithman J, et al. Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used. Cancer Immunol Immunother. 2021;70:3249–58.33835222 10.1007/s00262-021-02934-3
162. Delclaux I Ventre KS Jones D Lund AW The tumor-draining lymph node as a reservoir for systemic immune surveillance Trends Cancer 2024 10 28 37 10.1016/j.trecan.2023.09.006 37863720
Delclaux I, Ventre KS, Jones D, Lund AW. The tumor-draining lymph node as a reservoir for systemic immune surveillance. Trends Cancer. 2024;10:28–37.37863720 10.1016/j.trecan.2023.09.006
163. Schenkel JM Herbst RH Canner D Li A Hillman M Shanahan SL Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T cells in tumor-draining lymph nodes Immunity 2021 54 2338 53 10.1016/j.immuni.2021.08.026 34534439
Schenkel JM, Herbst RH, Canner D, Li A, Hillman M, Shanahan SL, et al. Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T cells in tumor-draining lymph nodes. Immunity. 2021;54:2338–53. e6.34534439 10.1016/j.immuni.2021.08.026
164. Roberts EW Broz ML Binnewies M Headley MB Nelson AE Wolf DM Critical role for CD103+/CD141+ dendritic cells bearing CCR7 for Tumor Antigen Trafficking and priming of T cell immunity in Melanoma Cancer Cell 2016 30 324 36 10.1016/j.ccell.2016.06.003 27424807
Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, et al. Critical role for CD103+/CD141+ dendritic cells bearing CCR7 for Tumor Antigen Trafficking and priming of T cell immunity in Melanoma. Cancer Cell. 2016;30:324–36.27424807 10.1016/j.ccell.2016.06.003
165. Broz ML Binnewies M Boldajipour B Nelson AE Pollack JL Erle DJ Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity Cancer Cell 2014 26 638 52 10.1016/j.ccell.2014.09.007 25446897
Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014;26:638–52.25446897 10.1016/j.ccell.2014.09.007
166. Heras-Murillo I, Adán-Barrientos I, Galán M, Wculek SK, Sancho D. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat Reviews Clin Oncol. 2024.
167. MacNabb BW, Tumuluru S, Chen X, Godfrey J, Kasal DN, Yu J et al. Dendritic cells can prime anti-tumor CD8+ T cell responses through major histocompatibility complex cross-dressing. Immunity. 2022;55:982 – 97.e8.
168. Ruhland MK, Roberts EW, Cai E, Mujal AM, Marchuk K, Beppler C et al. Visualizing synaptic transfer of Tumor antigens among dendritic cells. Cancer Cell. 2020;37:786 – 99.e5.
169. Ferris ST Durai V Wu R Theisen DJ Ward JP Bern MD cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity Nature 2020 584 624 9 10.1038/s41586-020-2611-3 32788723
Ferris ST, Durai V, Wu R, Theisen DJ, Ward JP, Bern MD, et al. cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity. Nature. 2020;584:624–9.32788723 10.1038/s41586-020-2611-3
170. Duong E, Fessenden TB, Lutz E, Dinter T, Yim L, Blatt S et al. Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. Immunity. 2022;55:308 – 23.e9.
171. Gurevich I Feferman T Milo I Tal O Golani O Drexler I Shakhar G Active dissemination of cellular antigens by DCs facilitates CD8+ T-cell priming in lymph nodes Eur J Immunol 2017 47 1802 18 10.1002/eji.201747042 28872666
Gurevich I, Feferman T, Milo I, Tal O, Golani O, Drexler I, Shakhar G. Active dissemination of cellular antigens by DCs facilitates CD8+ T-cell priming in lymph nodes. Eur J Immunol. 2017;47:1802–18.28872666 10.1002/eji.201747042
172. Pirillo C Al Khalidi S Sims A Devlin R Zhao H Pinto R Cotransfer of antigen and contextual information harmonizes peripheral and lymph node conventional dendritic cell activation Sci Immunol 2023 8 eadg8249 10.1126/sciimmunol.adg8249 37478193
Pirillo C, Al Khalidi S, Sims A, Devlin R, Zhao H, Pinto R, et al. Cotransfer of antigen and contextual information harmonizes peripheral and lymph node conventional dendritic cell activation. Sci Immunol. 2023;8:eadg8249.37478193 10.1126/sciimmunol.adg8249
173. Connolly KA Kuchroo M Venkat A Khatun A Wang J William I A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response Sci Immunol 2021 6 eabg7836 10.1126/sciimmunol.abg7836 34597124
Connolly KA, Kuchroo M, Venkat A, Khatun A, Wang J, William I, et al. A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response. Sci Immunol. 2021;6:eabg7836.34597124 10.1126/sciimmunol.abg7836
174. Prokhnevska N, Cardenas MA, Valanparambil RM, Sobierajska E, Barwick BG, Jansen C et al. CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity. 2023;56:107 – 24.e5.
175. Nagasaki J Inozume T Sax N Ariyasu R Ishikawa M Yamashita K PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes Cell Rep 2022 38 110331 10.1016/j.celrep.2022.110331 35108529
Nagasaki J, Inozume T, Sax N, Ariyasu R, Ishikawa M, Yamashita K, et al. PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes. Cell Rep. 2022;38:110331.35108529 10.1016/j.celrep.2022.110331
176. Dammeijer F van Gulijk M Mulder EE Lukkes M Klaase L van den Bosch T The PD-1/PD-L1-Checkpoint restrains T cell immunity in Tumor-Draining Lymph Nodes Cancer Cell 2020 38 685 e7008 10.1016/j.ccell.2020.09.001 33007259
Dammeijer F, van Gulijk M, Mulder EE, Lukkes M, Klaase L, van den Bosch T, et al. The PD-1/PD-L1-Checkpoint restrains T cell immunity in Tumor-Draining Lymph Nodes. Cancer Cell. 2020;38:685–e7008.33007259 10.1016/j.ccell.2020.09.001
177. Steele MM Jaiswal A Delclaux I Dryg ID Murugan D Femel J T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control Nat Immunol 2023 24 664 75 10.1038/s41590-023-01443-y 36849745
Steele MM, Jaiswal A, Delclaux I, Dryg ID, Murugan D, Femel J, et al. T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control. Nat Immunol. 2023;24:664–75.36849745 10.1038/s41590-023-01443-y
178. Pai JA, Hellmann MD, Sauter JL, Mattar M, Rizvi H, Woo HJ et al. Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. Cancer Cell. 2023;41:776 – 90.e7.
179. Francis DM, Manspeaker MP, Schudel A, Sestito LF, O’Melia MJ, Kissick HT et al. Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. Sci Transl Med. 2020;12.
180. Manspeaker MP, O’Melia MJ, Thomas SN. Elicitation of stem-like CD8+ T cell responses via lymph node-targeted chemoimmunotherapy evokes systemic tumor control. J Immunother Cancer. 2022;10.
181. Fransen MF, Schoonderwoerd M, Knopf P, Camps MG, Hawinkels LJ, Kneilling M et al. Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy. JCI Insight. 2018;3.
182. Yang H Sun B Ma W Fan L Xu K Jia Y Multi-scale characterization of tumor-draining lymph nodes in resectable lung cancer treated with neoadjuvant immune checkpoint inhibitors EBioMedicine 2022 84 104265 10.1016/j.ebiom.2022.104265 36116212
Yang H, Sun B, Ma W, Fan L, Xu K, Jia Y, et al. Multi-scale characterization of tumor-draining lymph nodes in resectable lung cancer treated with neoadjuvant immune checkpoint inhibitors. EBioMedicine. 2022;84:104265.36116212 10.1016/j.ebiom.2022.104265
183. Reticker-Flynn NE Zhang W Belk JA Basto PA Escalante NK Pilarowski GOW Lymph node colonization induces tumor-immune tolerance to promote distant metastasis Cell 2022 185 1924 42 10.1016/j.cell.2022.04.019 35525247
Reticker-Flynn NE, Zhang W, Belk JA, Basto PA, Escalante NK, Pilarowski GOW, et al. Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell. 2022;185:1924–42. .e23.35525247 10.1016/j.cell.2022.04.019
184. van Krimpen A Gerretsen VIV Mulder EEAP van Gulijk M van den Bosch TPP von der Thüsen J Immune suppression in the tumor-draining lymph node corresponds with distant disease recurrence in patients with melanoma Cancer Cell 2022 40 798 9 10.1016/j.ccell.2022.06.009 35839777
van Krimpen A, Gerretsen VIV, Mulder EEAP, van Gulijk M, van den Bosch TPP, von der Thüsen J, et al. Immune suppression in the tumor-draining lymph node corresponds with distant disease recurrence in patients with melanoma. Cancer Cell. 2022;40:798–9.35839777 10.1016/j.ccell.2022.06.009
185. Núñez NG Tosello Boari J Ramos RN Richer W Cagnard N Anderfuhren CD Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients Nat Commun 2020 11 3272 10.1038/s41467-020-17046-2 32601304
Núñez NG, Tosello Boari J, Ramos RN, Richer W, Cagnard N, Anderfuhren CD, et al. Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients. Nat Commun. 2020;11:3272.32601304 10.1038/s41467-020-17046-2
186. Baeyens A Fang V Chen C Schwab SR Exit strategies: S1P Signaling and T Cell Migration Trends Immunol 2015 36 778 87 10.1016/j.it.2015.10.005 26596799
Baeyens A, Fang V, Chen C, Schwab SR. Exit strategies: S1P Signaling and T Cell Migration. Trends Immunol. 2015;36:778–87.26596799 10.1016/j.it.2015.10.005
187. Nakai A Hayano Y Furuta F Noda M Suzuki K Control of lymphocyte egress from lymph nodes through β2-adrenergic receptors J Exp Med 2014 211 2583 98 10.1084/jem.20141132 25422496
Nakai A, Hayano Y, Furuta F, Noda M, Suzuki K. Control of lymphocyte egress from lymph nodes through β2-adrenergic receptors. J Exp Med. 2014;211:2583–98.25422496 10.1084/jem.20141132
188. Globig AM Zhao S Roginsky J Maltez VI Guiza J Avina-Ochoa N The β1-adrenergic receptor links sympathetic nerves to T cell exhaustion Nature 2023 622 383 92 10.1038/s41586-023-06568-6 37731001
Globig AM, Zhao S, Roginsky J, Maltez VI, Guiza J, Avina-Ochoa N, et al. The β1-adrenergic receptor links sympathetic nerves to T cell exhaustion. Nature. 2023;622:383–92.37731001 10.1038/s41586-023-06568-6
189. Ozga AJ Chow MT Luster AD Chemokines and the immune response to cancer Immunity 2021 54 859 74 10.1016/j.immuni.2021.01.012 33838745
Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer. Immunity. 2021;54:859–74.33838745 10.1016/j.immuni.2021.01.012
190. Chow MT, Ozga AJ, Servis RL, Frederick DT, Lo JA, Fisher DE et al. Intratumoral Activity of the CXCR3 chemokine system is required for the efficacy of Anti-PD-1 therapy. Immunity. 2019;50:1498 – 512.e5.
191. Di Pilato M Kfuri-Rubens R Pruessmann JN Ozga AJ Messemaker M Cadilha BL CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment Cell 2021 184 4512 e3022 10.1016/j.cell.2021.07.015 34343496
Di Pilato M, Kfuri-Rubens R, Pruessmann JN, Ozga AJ, Messemaker M, Cadilha BL, et al. CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell. 2021;184:4512–e3022.34343496 10.1016/j.cell.2021.07.015
192. Dangaj D Bruand M Grimm AJ Ronet C Barras D Duttagupta PA Cooperation between constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid tumors Cancer Cell 2019 35 885 e90010 10.1016/j.ccell.2019.05.004 31185212
Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, et al. Cooperation between constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid tumors. Cancer Cell. 2019;35:885–e90010.31185212 10.1016/j.ccell.2019.05.004
193. Hornburg M, Desbois M, Lu S, Guan Y, Lo AA, Kaufman S et al. Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. Cancer Cell. 2021;39:928 – 44.e6.
194. Li S Li K Wang K Yu H Wang X Shi M Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8+ exhausted-like T cells Nat Commun 2023 14 7709 10.1038/s41467-023-43462-1 38001101
Li S, Li K, Wang K, Yu H, Wang X, Shi M, et al. Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8+ exhausted-like T cells. Nat Commun. 2023;14:7709.38001101 10.1038/s41467-023-43462-1
195. Huijbers EJM Khan KA Kerbel RS Griffioen AW Tumors resurrect an embryonic vascular program to escape immunity Sci Immunol 2022 7 eabm6388 10.1126/sciimmunol.abm6388 35030032
Huijbers EJM, Khan KA, Kerbel RS, Griffioen AW. Tumors resurrect an embryonic vascular program to escape immunity. Sci Immunol. 2022;7:eabm6388.35030032 10.1126/sciimmunol.abm6388
196. Xu M Zhang T Xia R Wei Y Wei X Targeting the tumor stroma for cancer therapy Mol Cancer 2022 21 208 10.1186/s12943-022-01670-1 36324128
Xu M, Zhang T, Xia R, Wei Y, Wei X. Targeting the tumor stroma for cancer therapy. Mol Cancer. 2022;21:208.36324128 10.1186/s12943-022-01670-1
197. Holash J Maisonpierre PC Compton D Boland P Alexander CR Zagzag D Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 1999 284 1994 8 10.1126/science.284.5422.1994 10373119
Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999;284:1994–8.10373119 10.1126/science.284.5422.1994
198. Ohm JE Gabrilovich DI Sempowski GD Kisseleva E Parman KS Nadaf S Carbone DP VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression Blood 2003 101 4878 86 10.1182/blood-2002-07-1956 12586633
Ohm JE, Gabrilovich DI, Sempowski GD, Kisseleva E, Parman KS, Nadaf S, Carbone DP. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 2003;101:4878–86.12586633 10.1182/blood-2002-07-1956
199. Kim CG, Jang M, Kim Y, Leem G, Kim KH, Lee H et al. VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers. Sci Immunol. 2019;4.
200. Voron T Colussi O Marcheteau E Pernot S Nizard M Pointet AL VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors J Exp Med 2015 212 139 48 10.1084/jem.20140559 25601652
Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet AL, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212:139–48.25601652 10.1084/jem.20140559
201. Deng H Kan A Lyu N Mu L Han Y Liu L Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits Antitumor Immunity and enhances programmed cell Death-1 checkpoint blockade in Hepatocellular Carcinoma Liver Cancer 2020 9 338 57 10.1159/000505695 32647635
Deng H, Kan A, Lyu N, Mu L, Han Y, Liu L, et al. Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits Antitumor Immunity and enhances programmed cell Death-1 checkpoint blockade in Hepatocellular Carcinoma. Liver Cancer. 2020;9:338–57.32647635 10.1159/000505695
202. Liu S Qin T Liu Z Wang J Jia Y Feng Y Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells Cell Death Dis 2020 11 309 10.1038/s41419-020-2511-3 32366856
Liu S, Qin T, Liu Z, Wang J, Jia Y, Feng Y, et al. Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis. 2020;11:309.32366856 10.1038/s41419-020-2511-3
203. Crispen PL Sheinin Y Roth TJ Lohse CM Kuntz SM Frigola X Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma Clin Cancer Res 2008 14 5150 7 10.1158/1078-0432.CCR-08-0536 18694993
Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 2008;14:5150–7.18694993 10.1158/1078-0432.CCR-08-0536
204. Motz GT Santoro SP Wang L-P Garrabrant T Lastra RR Hagemann IS Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors Nat Med 2014 20 607 15 10.1038/nm.3541 24793239
Motz GT, Santoro SP, Wang L-P, Garrabrant T, Lastra RR, Hagemann IS, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20:607–15.24793239 10.1038/nm.3541
205. Dirkx AE Oude Egbrink MG Kuijpers MJ van der Niet ST Heijnen VV Bouma-ter Steege JC Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression Cancer Res 2003 63 2322 9 12727857
Dirkx AE, Oude Egbrink MG, Kuijpers MJ, van der Niet ST, Heijnen VV, Bouma-ter Steege JC, et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res. 2003;63:2322–9.12727857
206. Griffioen AW Damen CA Blijham GH Groenewegen G Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium Blood 1996 88 667 73 10.1182/blood.V88.2.667.bloodjournal882667 8695814
Griffioen AW, Damen CA, Blijham GH, Groenewegen G. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood. 1996;88:667–73.8695814 10.1182/blood.V88.2.667.bloodjournal882667
207. Huinen ZR Huijbers EJM van Beijnum JR Nowak-Sliwinska P Griffioen AW Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes Nat Reviews Clin Oncol 2021 18 527 40 10.1038/s41571-021-00496-y
Huinen ZR, Huijbers EJM, van Beijnum JR, Nowak-Sliwinska P, Griffioen AW. Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat Reviews Clin Oncol. 2021;18:527–40.10.1038/s41571-021-00496-y
208. Rini BI Plimack ER Stus V Gafanov R Hawkins R Nosov D Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma N Engl J Med 2019 380 1116 27 10.1056/NEJMoa1816714 30779529
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380:1116–27.30779529 10.1056/NEJMoa1816714
209. Motzer RJ Penkov K Haanen J Rini B Albiges L Campbell MT Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma N Engl J Med 2019 380 1103 15 10.1056/NEJMoa1816047 30779531
Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380:1103–15.30779531 10.1056/NEJMoa1816047
210. Finn RS Qin S Ikeda M Galle PR Ducreux M Kim T-Y Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma N Engl J Med 2020 382 1894 905 10.1056/NEJMoa1915745 32402160
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382:1894–905.32402160 10.1056/NEJMoa1915745
211. Socinski MA Jotte RM Cappuzzo F Orlandi F Stroyakovskiy D Nogami N Atezolizumab for First-Line treatment of metastatic nonsquamous NSCLC N Engl J Med 2018 378 2288 301 10.1056/NEJMoa1716948 29863955
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for First-Line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–301.29863955 10.1056/NEJMoa1716948
212. Makker V Colombo N Casado Herráez A Santin AD Colomba E Miller DS Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer N Engl J Med 2022 386 437 48 10.1056/NEJMoa2108330 35045221
Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, et al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med. 2022;386:437–48.35045221 10.1056/NEJMoa2108330
213. Meng X Wu T Hong Y Fan Q Ren Z Guo Y Camrelizumab plus Apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial Lancet Gastroenterol Hepatol 2022 7 245 53 10.1016/S2468-1253(21)00378-2 34998471
Meng X, Wu T, Hong Y, Fan Q, Ren Z, Guo Y, et al. Camrelizumab plus Apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7:245–53.34998471 10.1016/S2468-1253(21)00378-2
214. Asrir A, Tardiveau C, Coudert J, Laffont R, Blanchard L, Bellard E et al. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell. 2022;40:318 – 34.e9.
215. Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017;9.
216. Hua Y, Vella G, Rambow F, Allen E, Antoranz Martinez A, Duhamel M et al. Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop. Cancer Cell. 2022;40:1600-18.e10.
217. Frankenstein Z Basanta D Franco OE Gao Y Javier RA Strand DW Stromal reactivity differentially drives tumour cell evolution and prostate cancer progression Nat Ecol Evol 2020 4 870 84 10.1038/s41559-020-1157-y 32393869
Frankenstein Z, Basanta D, Franco OE, Gao Y, Javier RA, Strand DW, et al. Stromal reactivity differentially drives tumour cell evolution and prostate cancer progression. Nat Ecol Evol. 2020;4:870–84.32393869 10.1038/s41559-020-1157-y
218. Zhao Y Shen M Wu L Yang H Yao Y Yang Q Stromal cells in the tumor microenvironment: accomplices of tumor progression? Cell Death Dis 2023 14 587 10.1038/s41419-023-06110-6 37666813
Zhao Y, Shen M, Wu L, Yang H, Yao Y, Yang Q, et al. Stromal cells in the tumor microenvironment: accomplices of tumor progression? Cell Death Dis. 2023;14:587.37666813 10.1038/s41419-023-06110-6
219. Cords L, Engler S, Haberecker M, Rüschoff JH, Moch H, de Souza N, Bodenmiller B. Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer. Cancer Cell. 2024.
220. Buechler MB Pradhan RN Krishnamurty AT Cox C Calviello AK Wang AW Cross-tissue organization of the fibroblast lineage Nature 2021 593 575 9 10.1038/s41586-021-03549-5 33981032
Buechler MB, Pradhan RN, Krishnamurty AT, Cox C, Calviello AK, Wang AW, et al. Cross-tissue organization of the fibroblast lineage. Nature. 2021;593:575–9.33981032 10.1038/s41586-021-03549-5
221. Grout JA Sirven P Leader AM Maskey S Hector E Puisieux I Spatial positioning and Matrix Programs of Cancer-Associated fibroblasts promote T-cell exclusion in human lung tumors Cancer Discov 2022 12 2606 25 10.1158/2159-8290.CD-21-1714 36027053
Grout JA, Sirven P, Leader AM, Maskey S, Hector E, Puisieux I, et al. Spatial positioning and Matrix Programs of Cancer-Associated fibroblasts promote T-cell exclusion in human lung tumors. Cancer Discov. 2022;12:2606–25.36027053 10.1158/2159-8290.CD-21-1714
222. Krishnamurty AT Shyer JA Thai M Gandham V Buechler MB Yang YA LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity Nature 2022 611 148 54 10.1038/s41586-022-05272-1 36171287
Krishnamurty AT, Shyer JA, Thai M, Gandham V, Buechler MB, Yang YA, et al. LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature. 2022;611:148–54.36171287 10.1038/s41586-022-05272-1
223. Caligiuri G Tuveson DA Activated fibroblasts in cancer: perspectives and challenges Cancer Cell 2023 41 434 49 10.1016/j.ccell.2023.02.015 36917949
Caligiuri G, Tuveson DA. Activated fibroblasts in cancer: perspectives and challenges. Cancer Cell. 2023;41:434–49.36917949 10.1016/j.ccell.2023.02.015
224. Ma C Yang C Peng A Sun T Ji X Mi J Pan-cancer spatially resolved single-cell analysis reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment Mol Cancer 2023 22 170 10.1186/s12943-023-01876-x 37833788
Ma C, Yang C, Peng A, Sun T, Ji X, Mi J, et al. Pan-cancer spatially resolved single-cell analysis reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment. Mol Cancer. 2023;22:170.37833788 10.1186/s12943-023-01876-x
225. Luo H Xia X Huang L-B An H Cao M Kim GD Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment Nat Commun 2022 13 6619 10.1038/s41467-022-34395-2 36333338
Luo H, Xia X, Huang L-B, An H, Cao M, Kim GD, et al. Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment. Nat Commun. 2022;13:6619.36333338 10.1038/s41467-022-34395-2
226. Elyada E Bolisetty M Laise P Flynn WF Courtois ET Burkhart RA Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals Antigen-Presenting Cancer-Associated fibroblasts Cancer Discov 2019 9 1102 23 10.1158/2159-8290.CD-19-0094 31197017
Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals Antigen-Presenting Cancer-Associated fibroblasts. Cancer Discov. 2019;9:1102–23.31197017 10.1158/2159-8290.CD-19-0094
227. Jenkins L Jungwirth U Avgustinova A Iravani M Mills A Haider S Cancer-Associated fibroblasts suppress CD8+ T-cell infiltration and Confer Resistance to Immune-Checkpoint Blockade Cancer Res 2022 82 2904 17 10.1158/0008-5472.CAN-21-4141 35749591
Jenkins L, Jungwirth U, Avgustinova A, Iravani M, Mills A, Haider S, et al. Cancer-Associated fibroblasts suppress CD8+ T-cell infiltration and Confer Resistance to Immune-Checkpoint Blockade. Cancer Res. 2022;82:2904–17.35749591 10.1158/0008-5472.CAN-21-4141
228. Kieffer Y Hocine HR Gentric G Pelon F Bernard C Bourachot B Single-cell analysis reveals fibroblast clusters linked to Immunotherapy Resistance in Cancer Cancer Discov 2020 10 1330 51 10.1158/2159-8290.CD-19-1384 32434947
Kieffer Y, Hocine HR, Gentric G, Pelon F, Bernard C, Bourachot B, et al. Single-cell analysis reveals fibroblast clusters linked to Immunotherapy Resistance in Cancer. Cancer Discov. 2020;10:1330–51.32434947 10.1158/2159-8290.CD-19-1384
229. Chakravarthy A Khan L Bensler NP Bose P De Carvalho DD TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure Nat Commun 2018 9 4692 10.1038/s41467-018-06654-8 30410077
Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD. TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat Commun. 2018;9:4692.30410077 10.1038/s41467-018-06654-8
230. Peng DH Rodriguez BL Diao L Chen L Wang J Byers LA Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion Nat Commun 2020 11 4520 10.1038/s41467-020-18298-8 32908154
Peng DH, Rodriguez BL, Diao L, Chen L, Wang J, Byers LA, et al. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. Nat Commun. 2020;11:4520.32908154 10.1038/s41467-020-18298-8
231. Pruitt HC, Lewis D, Ciccaglione M, Connor S, Smith Q, Hickey JW et al. Collagen fiber structure guides 3D motility of cytotoxic T lymphocytes. Matrix Biol. 2020;85–6:147–59.
232. Salmon H Franciszkiewicz K Damotte D Dieu-Nosjean MC Validire P Trautmann A Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors J Clin Invest 2012 122 899 910 10.1172/JCI45817 22293174
Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A, et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest. 2012;122:899–910.22293174 10.1172/JCI45817
233. Mariathasan S Turley SJ Nickles D Castiglioni A Yuen K Wang Y TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells Nature 2018 554 544 8 10.1038/nature25501 29443960
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544–8.29443960 10.1038/nature25501
234. Costa A Kieffer Y Scholer-Dahirel A Pelon F Bourachot B Cardon M Fibroblast heterogeneity and immunosuppressive environment in human breast Cancer Cancer Cell 2018 33 463 10.1016/j.ccell.2018.01.011 29455927
Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast Cancer. Cancer Cell. 2018;33:463–. – 79.e10.29455927 10.1016/j.ccell.2018.01.011
235. Kato T Noma K Ohara T Kashima H Katsura Y Sato H Cancer-Associated fibroblasts affect Intratumoral CD8+ and FoxP3+ T cells Via IL6 in the Tumor Microenvironment Clin Cancer Res 2018 24 4820 33 10.1158/1078-0432.CCR-18-0205 29921731
Kato T, Noma K, Ohara T, Kashima H, Katsura Y, Sato H, et al. Cancer-Associated fibroblasts affect Intratumoral CD8+ and FoxP3+ T cells Via IL6 in the Tumor Microenvironment. Clin Cancer Res. 2018;24:4820–33.29921731 10.1158/1078-0432.CCR-18-0205
236. Qi J Sun H Zhang Y Wang Z Xun Z Li Z Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and SPP1+ macrophages in colorectal cancer Nat Commun 2022 13 1742 10.1038/s41467-022-29366-6 35365629
Qi J, Sun H, Zhang Y, Wang Z, Xun Z, Li Z, et al. Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and SPP1+ macrophages in colorectal cancer. Nat Commun. 2022;13:1742.35365629 10.1038/s41467-022-29366-6
237. Wu SZ Roden DL Wang C Holliday H Harvey K Cazet AS Stromal cell diversity associated with immune evasion in human triple-negative breast cancer Embo j 2020 39 e104063 10.15252/embj.2019104063 32790115
Wu SZ, Roden DL, Wang C, Holliday H, Harvey K, Cazet AS, et al. Stromal cell diversity associated with immune evasion in human triple-negative breast cancer. Embo j. 2020;39:e104063.32790115 10.15252/embj.2019104063
238. Zhao Q Huang L Qin G Qiao Y Ren F Shen C Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma Cancer Lett 2021 518 35 48 10.1016/j.canlet.2021.06.009 34139285
Zhao Q, Huang L, Qin G, Qiao Y, Ren F, Shen C, et al. Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma. Cancer Lett. 2021;518:35–48.34139285 10.1016/j.canlet.2021.06.009
239. Feig C Jones JO Kraman M Wells RJ Deonarine A Chan DS Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer Proc Natl Acad Sci U S A 2013 110 20212 7 10.1073/pnas.1320318110 24277834
Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110:20212–7.24277834 10.1073/pnas.1320318110
240. Li C Guo H Zhai P Yan M Liu C Wang X Spatial and single-cell transcriptomics reveal a Cancer-Associated Fibroblast Subset in HNSCC that restricts infiltration and antitumor activity of CD8+ T cells Cancer Res 2024 84 258 75 10.1158/0008-5472.CAN-23-1448 37930937
Li C, Guo H, Zhai P, Yan M, Liu C, Wang X, et al. Spatial and single-cell transcriptomics reveal a Cancer-Associated Fibroblast Subset in HNSCC that restricts infiltration and antitumor activity of CD8+ T cells. Cancer Res. 2024;84:258–75.37930937 10.1158/0008-5472.CAN-23-1448
241. Yang W Liu S Mao M Gong Y Li X Lei T T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution J Exp Clin Cancer Res 2024 43 38 10.1186/s13046-024-02960-w 38303018
Yang W, Liu S, Mao M, Gong Y, Li X, Lei T, et al. T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution. J Exp Clin Cancer Res. 2024;43:38.38303018 10.1186/s13046-024-02960-w
242. Zboralski D Hoehlig K Eulberg D Frömming A Vater A Increasing tumor-infiltrating T cells through inhibition of CXCL12 with NOX-A12 synergizes with PD-1 blockade Cancer Immunol Res 2017 5 950 6 10.1158/2326-6066.CIR-16-0303 28963140
Zboralski D, Hoehlig K, Eulberg D, Frömming A, Vater A. Increasing tumor-infiltrating T cells through inhibition of CXCL12 with NOX-A12 synergizes with PD-1 blockade. Cancer Immunol Res. 2017;5:950–6.28963140 10.1158/2326-6066.CIR-16-0303
243. Sathe A Mason K Grimes SM Zhou Z Lau BT Bai X Colorectal Cancer metastases in the liver establish immunosuppressive spatial networking between Tumor-Associated SPP1+ macrophages and fibroblasts Clin Cancer Res 2023 29 244 60 10.1158/1078-0432.CCR-22-2041 36239989
Sathe A, Mason K, Grimes SM, Zhou Z, Lau BT, Bai X, et al. Colorectal Cancer metastases in the liver establish immunosuppressive spatial networking between Tumor-Associated SPP1+ macrophages and fibroblasts. Clin Cancer Res. 2023;29:244–60.36239989 10.1158/1078-0432.CCR-22-2041
244. Timperi E Gueguen P Molgora M Magagna I Kieffer Y Lopez-Lastra S Lipid-Associated macrophages Are Induced by Cancer-Associated fibroblasts and mediate Immune suppression in breast Cancer Cancer Res 2022 82 3291 306 10.1158/0008-5472.CAN-22-1427 35862581
Timperi E, Gueguen P, Molgora M, Magagna I, Kieffer Y, Lopez-Lastra S, et al. Lipid-Associated macrophages Are Induced by Cancer-Associated fibroblasts and mediate Immune suppression in breast Cancer. Cancer Res. 2022;82:3291–306.35862581 10.1158/0008-5472.CAN-22-1427
245. Huang H, Wang Z, Zhang Y, Pradhan RN, Ganguly D, Chandra R et al. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell. 2022;40:656 – 73.e7.
246. Lakins MA Ghorani E Munir H Martins CP Shields JD Cancer-associated fibroblasts induce antigen-specific deletion of CD8+ T cells to protect tumour cells Nat Commun 2018 9 948 10.1038/s41467-018-03347-0 29507342
Lakins MA, Ghorani E, Munir H, Martins CP, Shields JD. Cancer-associated fibroblasts induce antigen-specific deletion of CD8+ T cells to protect tumour cells. Nat Commun. 2018;9:948.29507342 10.1038/s41467-018-03347-0
247. Kerdidani D, Aerakis E, Verrou KM, Angelidis I, Douka K, Maniou MA et al. Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts. J Exp Med. 2022;219.
248. Hutton C Heider F Blanco-Gomez A Banyard A Kononov A Zhang X Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity Cancer Cell 2021 39 1227 e4420 10.1016/j.ccell.2021.06.017 34297917
Hutton C, Heider F, Blanco-Gomez A, Banyard A, Kononov A, Zhang X, et al. Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity. Cancer Cell. 2021;39:1227–e4420.34297917 10.1016/j.ccell.2021.06.017
249. Xiao Z Todd L Huang L Noguera-Ortega E Lu Z Huang L Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors Nat Commun 2023 14 5110 10.1038/s41467-023-40850-5 37607999
Xiao Z, Todd L, Huang L, Noguera-Ortega E, Lu Z, Huang L, et al. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nat Commun. 2023;14:5110.37607999 10.1038/s41467-023-40850-5
250. Chen Y, Kim J, Yang S, Wang H, Wu CJ, Sugimoto H et al. Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. Cancer Cell. 2021;39:548 – 65.e6.
251. Bhattacharjee S, Hamberger F, Ravichandra A, Miller M, Nair A, Affo S et al. Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. J Clin Invest. 2021;131.
252. Verma NK, Wong BHS, Poh ZS, Udayakumar A, Verma R, Goh RKJ et al. Obstacles for T-lymphocytes in the tumour microenvironment: therapeutic challenges, advances and opportunities beyond immune checkpoint. eBioMedicine. 2022;83.
253. Liu X Hoft DF Peng G Tumor microenvironment metabolites directing T cell differentiation and function Trends Immunol 2022 43 132 47 10.1016/j.it.2021.12.004 34973923
Liu X, Hoft DF, Peng G. Tumor microenvironment metabolites directing T cell differentiation and function. Trends Immunol. 2022;43:132–47.34973923 10.1016/j.it.2021.12.004
254. Goc J Germain C Vo-Bourgais TKD Lupo A Klein C Knockaert S Dendritic cells in Tumor-Associated Tertiary lymphoid structures signal a Th1 cytotoxic Immune contexture and license the positive prognostic value of infiltrating CD8+ T cells Cancer Res 2014 74 705 15 10.1158/0008-5472.CAN-13-1342 24366885
Goc J, Germain C, Vo-Bourgais TKD, Lupo A, Klein C, Knockaert S, et al. Dendritic cells in Tumor-Associated Tertiary lymphoid structures signal a Th1 cytotoxic Immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 2014;74:705–15.24366885 10.1158/0008-5472.CAN-13-1342
255. Humblin E Korpas I Lu J Filipescu D van der Heide V Goldstein S Sustained CD28 costimulation is required for self-renewal and differentiation of TCF-1+ PD-1+ CD8 T cells Sci Immunol 2023 8 eadg0878 10.1126/sciimmunol.adg0878 37624910
Humblin E, Korpas I, Lu J, Filipescu D, van der Heide V, Goldstein S, et al. Sustained CD28 costimulation is required for self-renewal and differentiation of TCF-1+ PD-1+ CD8 T cells. Sci Immunol. 2023;8:eadg0878.37624910 10.1126/sciimmunol.adg0878
256. Im SJ Obeng RC Nasti TH McManus D Kamphorst AO Gunisetty S Characteristics and anatomic location of PD-1+TCF1+ stem-like CD8 T cells in chronic viral infection and cancer Proc Natl Acad Sci U S A 2023 120 e2221985120 10.1073/pnas.2221985120 37782797
Im SJ, Obeng RC, Nasti TH, McManus D, Kamphorst AO, Gunisetty S, et al. Characteristics and anatomic location of PD-1+TCF1+ stem-like CD8 T cells in chronic viral infection and cancer. Proc Natl Acad Sci U S A. 2023;120:e2221985120.37782797 10.1073/pnas.2221985120
257. Meiser P, Knolle MA, Hirschberger A, de Almeida GP, Bayerl F, Lacher S et al. A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity. Cancer Cell. 2023;41:1498 – 515.e10.
258. Dixon KO Tabaka M Schramm MA Xiao S Tang R Dionne D TIM-3 restrains anti-tumour immunity by regulating inflammasome activation Nature 2021 595 101 6 10.1038/s41586-021-03626-9 34108686
Dixon KO, Tabaka M, Schramm MA, Xiao S, Tang R, Dionne D, et al. TIM-3 restrains anti-tumour immunity by regulating inflammasome activation. Nature. 2021;595:101–6.34108686 10.1038/s41586-021-03626-9
259. Lee CYC Kennedy BC Richoz N Dean I Tuong ZK Gaspal F Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity Nat Commun 2024 15 682 10.1038/s41467-024-44787-1 38267413
Lee CYC, Kennedy BC, Richoz N, Dean I, Tuong ZK, Gaspal F, et al. Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity. Nat Commun. 2024;15:682.38267413 10.1038/s41467-024-44787-1
260. Duraiswamy J Turrini R Minasyan A Barras D Crespo I Grimm AJ Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation Cancer Cell 2021 39 1623 e4220 10.1016/j.ccell.2021.10.008 34739845
Duraiswamy J, Turrini R, Minasyan A, Barras D, Crespo I, Grimm AJ, et al. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer Cell. 2021;39:1623–e4220.34739845 10.1016/j.ccell.2021.10.008
261. Maier B Leader AM Chen ST Tung N Chang C LeBerichel J A conserved dendritic-cell regulatory program limits antitumour immunity Nature 2020 580 257 62 10.1038/s41586-020-2134-y 32269339
Maier B, Leader AM, Chen ST, Tung N, Chang C, LeBerichel J, et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature. 2020;580:257–62.32269339 10.1038/s41586-020-2134-y
262. Bayerl F Meiser P Donakonda S Hirschberger A Lacher SB Pedde AM Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses Immunity 2023 56 1341 e5811 10.1016/j.immuni.2023.05.011 37315536
Bayerl F, Meiser P, Donakonda S, Hirschberger A, Lacher SB, Pedde AM, et al. Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses. Immunity. 2023;56:1341–e5811.37315536 10.1016/j.immuni.2023.05.011
263. Cohen M Giladi A Barboy O Hamon P Li B Zada M The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response Nat Cancer 2022 3 303 17 10.1038/s43018-022-00338-5 35241835
Cohen M, Giladi A, Barboy O, Hamon P, Li B, Zada M, et al. The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response. Nat Cancer. 2022;3:303–17.35241835 10.1038/s43018-022-00338-5
264. Sato Y Silina K van den Broek M Hirahara K Yanagita M The roles of tertiary lymphoid structures in chronic diseases Nat Rev Nephrol 2023 19 525 37 10.1038/s41581-023-00706-z 37046081
Sato Y, Silina K, van den Broek M, Hirahara K, Yanagita M. The roles of tertiary lymphoid structures in chronic diseases. Nat Rev Nephrol. 2023;19:525–37.37046081 10.1038/s41581-023-00706-z
265. Cabrita R Lauss M Sanna A Donia M Skaarup Larsen M Mitra S Tertiary lymphoid structures improve immunotherapy and survival in melanoma Nature 2020 577 561 5 10.1038/s41586-019-1914-8 31942071
Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577:561–5.31942071 10.1038/s41586-019-1914-8
266. Petitprez F de Reyniès A Keung EZ Chen TW-W Sun C-M Calderaro J B cells are associated with survival and immunotherapy response in sarcoma Nature 2020 577 556 60 10.1038/s41586-019-1906-8 31942077
Petitprez F, de Reyniès A, Keung EZ, Chen TW-W, Sun C-M, Calderaro J, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577:556–60.31942077 10.1038/s41586-019-1906-8
267. Vanhersecke L Brunet M Guégan JP Rey C Bougouin A Cousin S Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression Nat Cancer 2021 2 794 802 10.1038/s43018-021-00232-6 35118423
Vanhersecke L, Brunet M, Guégan JP, Rey C, Bougouin A, Cousin S, et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer. 2021;2:794–802.35118423 10.1038/s43018-021-00232-6
268. Sawada J Hiraoka N Qi R Jiang L Fournier-Goss AE Yoshida M Molecular signature of Tumor-Associated High Endothelial venules that can predict breast Cancer survival Cancer Immunol Res 2022 10 468 81 10.1158/2326-6066.CIR-21-0369 35201289
Sawada J, Hiraoka N, Qi R, Jiang L, Fournier-Goss AE, Yoshida M, et al. Molecular signature of Tumor-Associated High Endothelial venules that can predict breast Cancer survival. Cancer Immunol Res. 2022;10:468–81.35201289 10.1158/2326-6066.CIR-21-0369
269. Patil NS Nabet BY Müller S Koeppen H Zou W Giltnane J Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer Cancer Cell 2022 40 289 e3004 10.1016/j.ccell.2022.02.002 35216676
Patil NS, Nabet BY, Müller S, Koeppen H, Zou W, Giltnane J, et al. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell. 2022;40:289–e3004.35216676 10.1016/j.ccell.2022.02.002
270. Helmink BA Reddy SM Gao J Zhang S Basar R Thakur R B cells and tertiary lymphoid structures promote immunotherapy response Nature 2020 577 549 55 10.1038/s41586-019-1922-8 31942075
Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577:549–55.31942075 10.1038/s41586-019-1922-8
271. Bruno TC New predictors for immunotherapy responses sharpen our view of the tumour microenvironment Nature 2020 577 474 6 10.1038/d41586-019-03943-0 31965091
Bruno TC. New predictors for immunotherapy responses sharpen our view of the tumour microenvironment. Nature. 2020;577:474–6.31965091 10.1038/d41586-019-03943-0
272. Thommen DS Koelzer VH Herzig P Roller A Trefny M Dimeloe S A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade Nat Med 2018 24 994 1004 10.1038/s41591-018-0057-z 29892065
Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, et al. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 2018;24:994–1004.29892065 10.1038/s41591-018-0057-z
273. Xu W, Lu J, Liu WR, Anwaier A, Wu Y, Tian X et al. Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma. J Immunother Cancer. 2023;11.
274. Masuda T, Tanaka N, Takamatsu K, Hakozaki K, Takahashi R, Anno T et al. Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer. J Immunother Cancer. 2022;10.
275. Liu B Zhang Y Wang D Hu X Zhang Z Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade Nat Cancer 2022 3 1123 36 10.1038/s43018-022-00433-7 36138134
Liu B, Zhang Y, Wang D, Hu X, Zhang Z. Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade. Nat Cancer. 2022;3:1123–36.36138134 10.1038/s43018-022-00433-7
276. Dai S Zeng H Liu Z Jin K Jiang W Wang Z Intratumoral CXCL13+CD8+T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma J Immunother Cancer 2021 9 e001823 10.1136/jitc-2020-001823 33589528
Dai S, Zeng H, Liu Z, Jin K, Jiang W, Wang Z, et al. Intratumoral CXCL13+CD8+T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma. J Immunother Cancer. 2021;9:e001823.33589528 10.1136/jitc-2020-001823
277. Simoni Y Becht E Fehlings M Loh CY Koo S-L Teng KWW Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates Nature 2018 557 575 9 10.1038/s41586-018-0130-2 29769722
Simoni Y, Becht E, Fehlings M, Loh CY, Koo S-L, Teng KWW, et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018;557:575–9.29769722 10.1038/s41586-018-0130-2
278. Borràs DM Verbandt S Ausserhofer M Sturm G Lim J Verge GA Single cell dynamics of tumor specificity vs bystander activity in CD8+ T cells define the diverse immune landscapes in colorectal cancer Cell Discov 2023 9 114 10.1038/s41421-023-00605-4 37968259
Borràs DM, Verbandt S, Ausserhofer M, Sturm G, Lim J, Verge GA, et al. Single cell dynamics of tumor specificity vs bystander activity in CD8+ T cells define the diverse immune landscapes in colorectal cancer. Cell Discov. 2023;9:114.37968259 10.1038/s41421-023-00605-4
279. Kirschenbaum D, Xie K, Ingelfinger F, Katzenelenbogen Y, Abadie K, Look T et al. Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma. Cell. 2024;187:149 – 65.e23.
280. Jia D Wang Q Qi Y Jiang Y He J Lin Y Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer Cell 2024 187 1651 e6521 10.1016/j.cell.2024.02.022 38490195
Jia D, Wang Q, Qi Y, Jiang Y, He J, Lin Y, et al. Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer. Cell. 2024;187:1651–e6521.38490195 10.1016/j.cell.2024.02.022
281. Mullard A. FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers 2024 [cited 2024 March 30]. https://www.nature.com/articles/d41573-024-00035-1
